EP1309620A2 - Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese - Google Patents

Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese

Info

Publication number
EP1309620A2
EP1309620A2 EP01957073A EP01957073A EP1309620A2 EP 1309620 A2 EP1309620 A2 EP 1309620A2 EP 01957073 A EP01957073 A EP 01957073A EP 01957073 A EP01957073 A EP 01957073A EP 1309620 A2 EP1309620 A2 EP 1309620A2
Authority
EP
European Patent Office
Prior art keywords
seq
sequence
acid sequence
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01957073A
Other languages
German (de)
English (en)
Inventor
Kevin P. Baker
Napoleone Ferrara
Hanspeter Gerber
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Kenneth J. Hillan
Scot A. Marsters
James Pan
Nicholas F. Paoni
Jean-Philippe F. Stephan
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Weilan Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from US09/643,657 external-priority patent/US6642024B1/en
Priority claimed from PCT/US2000/023522 external-priority patent/WO2001016319A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from US09/747,259 external-priority patent/US6569645B2/en
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Priority claimed from US09/767,609 external-priority patent/US20020042367A1/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/fr
Priority claimed from PCT/US2001/006666 external-priority patent/WO2001066740A2/fr
Priority claimed from US09/816,744 external-priority patent/US6579520B2/en
Priority claimed from US09/828,366 external-priority patent/US20020010137A1/en
Priority claimed from US09/854,280 external-priority patent/US7115398B2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/fr
Priority claimed from US09/866,028 external-priority patent/US6642360B2/en
Priority claimed from US09/866,034 external-priority patent/US20030170864A1/en
Priority claimed from PCT/US2001/017443 external-priority patent/WO2002016611A2/fr
Priority claimed from US09/870,574 external-priority patent/US6551799B2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/fr
Priority to EP08019420.2A priority Critical patent/EP2042597B1/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to DK08019420.2T priority patent/DK2042597T3/da
Priority to EP10182597A priority patent/EP2275549A1/fr
Priority to EP09004418A priority patent/EP2075253A1/fr
Priority to EP09004417A priority patent/EP2077276A1/fr
Priority to EP09004415A priority patent/EP2168980A1/fr
Priority to EP14166919.2A priority patent/EP2792747A1/fr
Publication of EP1309620A2 publication Critical patent/EP1309620A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to compositions and methods useful for the modulation (e.g., promotion or inhibition) of angiogenesis and or cardiovascularization in mammals in need of such biological effect.
  • the present invention further relates to the diagnosis and treatment of disorders involving angiogenesis (e.g. , cardiovascular as well as oncological disorders).
  • Angiogenesis defined as the growth or sprouting of new blood vessels from existing vessels, is a complex process that primarily occurs during embryonic development. Under normal physiological conditions in adults, angiogenesis takes place only in very restricted situations such as hair growth and wounding healing (Auerbach,
  • Unregulated angiogenesis has gradually been recognized to be responsible for a wide range of disorders, including, but not limited to cardiovascular disease, cancer, rheumatoid arthritis, psoriasis and diabetic retinopathy (Folkman, ⁇ 995, NatMed l(l):27-31; Isner, 1999, Circulation 99(13): 1653-5; Koch, 1998, Arthritis Rheum 41(6):951-62; Walsh, 1999, Rheumatology (Oxford) 38(2): 103-12; Ware and Simons,
  • CHF congestive heart failure
  • At least four major compensatory mechanisms are activated in the setting of heart failure to boost cardiac output, including peripheral vasoconstriction, increased heart rate, increased cardiac contractility, and increased plasma volume. These effects are mediated primarily by the sympathetic nervous system and the renin-angiotensin system. See, Eichhorn, American Journal of Medicine. 104: 163-169 (1998). Increased output from the sympathetic nervous system increases vascular tone, heart rate, and contractility.
  • Angiotensin II elevates blood pressure by 1) directly stimulating vascular smooth muscle contraction, 2) promoting plasma volume expansion by stimulating aldosterone and antidiuretic hormone secretion, 3) stimulating sympathetic-mediated vascular tone, and 4) catalyzing the degradation of bradykinin, which has vasodilatory and natriuretic activity.
  • angiotensin II may also have directly deleterious effects on the heart by promoting myocyte necrosis (impairing systolic function) and intracardiac fibrosis (impairing diastolic and in some cases systolic function). See, Weber, Circulation. 96: 4065-4082 (1998).
  • cardiac hypertrophy an enlargement of the heart that is activated by both mechanical and hormonal stimuli and enables the heart to adapt to demands for increased cardiac output.
  • This hypertrophic response is frequently associated with a variety of distinct pathological conditions such as hypertension, aortic stenosis, myocardial infarction, cardiomyopathy, valvular regurgitation, and intracardiac shunt, all of which result in chronic hemodynamic overload.
  • Hypertrophy is generally defined as an increase in size of an organ or structure independent of natural growth that does not involve tumor formation. Hypertrophy of the heart is due either to an increase in the mass of the individual cells (myocytes), or to an increase in the number of cells making up the tissue (hyperplasia), or both. While the enlargement of an embryonic heart is largely dependent on an increase in myocyte number (which continues until shortly after birth), post-natal cardiac myocytes lose their proliferative capacity. Further growth occurs through hypertrophy of the individual cells.
  • Adult myocyte hypertrophy is initially beneficial as a short term response to impaired cardiac function by permitting a decrease in the load on individual muscle fibers. With severe, long-standing overload, however, the hypertrophied cells begin to deteriorate and die.
  • non-myocytes On a cellular level, the heart is composed of myocytes and surrounding support cells, generically called non-myocytes. While non-myocytes are primarily fibroblast/mesenchymal cells, they also include endothelial and smooth muscle cells. Indeed, although myocytes make up most of the adult myocardial mass, they represent only about 30% of the total cell numbers present in heart. In response to hormonal, physiological, hemodynamic, and pathological stimuli, adult ventricular muscle cells can adapt to increased workloads through the activation of a hypertrophic process. This response is characterized by an increase in myocyte cell size and contractile protein content of individual cardiac muscle cells, without concomitant cell division and activation of embryonic genes, including the gene for atrial natriuretic peptide (ANP).
  • APN atrial natriuretic peptide
  • non-myocyte supporting cells may additionally be involved in the development of cardiac hypertrophy, and various non-myocyte derived hypertrophic factors, such as, leukocyte inhibitory factor (LIF) and endothelin, have been identified.
  • LIF leukocyte inhibitory factor
  • Metcalf Growth Factors.
  • cardiac hypertrophy varies depending on the underlying cardiac disease.
  • Catecholamines, adrenocorticosteroids, angiotensin, prostaglandins, LIF, endothelin (including endothelin- 1, -2, and -3 and big endotlielin), and CT-1 are among the factors identified as potential mediators of hypertrophy.
  • beta-adrenergic receptor blocking drugs e.g., propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, carvedilol, etc.
  • verapamil have been used extensively in the treatment of hypertrophic cardiomyopathy.
  • the beneficial effects of beta-blockers on symptoms (e.g., chest pain) and exercise tolerance are largely due to a decrease in the heart rate with a consequent prolongation of diastole and increased passive ventricular filling. Thompson et al, Br.
  • Nifedipine and diltiazem have also been used occasionally in the treatment of hypertrophic cardiomyopathy. Lorell et al, Circulation. 65: 499-507 (1982); Betocchi et al, Am. J. Cardiol.. 78: 451-457 (1996).
  • nifedipine may be harmful, especially in patients with outflow obstruction.
  • Disopyramide has been used to relieve symptoms by virtue of its negative inotropic properties. Pollick. N. Engl. J. Med blend 307: 997-999 (1982). In many patients, however, the initial benefits decrease with time. Wigle et al, Circulation. 92: 1680-1692 (1995).
  • Antihypertensive drug therapy has been reported to have beneficial effects on cardiac hypertrophy associated with elevated blood pressure.
  • drugs used in antihypertensive therapy are calcium antagonists, e.g. , nitrendipine; adrenergic receptor blocking agents, e.g., those listed above; angiotensin converting enzyme (ACE) inhibitors such as quinapril, captopril, enalapril, ramipril, benazepril, fosinopril, and lisinopril; diuretics, e.g., chlorothiazide, hydrochlorothiazide, hydroflumethazide, methylchlothiazide, benzthiazide, dichlo ⁇ henamide, acetazolamide, and indapamide; and calcium channel blockers, e.g., diltiazem, nifedipine, verapamil, and nicardipin
  • CHF CHF. Another treatment modality is heart transplantation, but this is limited by the availability of donor hearts.
  • Endothelin is a vasoconstricting peptide comprising 21 amino acids, isolated from swine arterial endothelial culture supernatant and structurally determined. Yanagisawa et al, Nature. 332: 411-415 (1988). Endothelin was later found to exhibit various actions, and endothelin antibodies as endothelin antagonists have proven effective in the treatment of myocardial infarction, renal failure, and other diseases. Since endothelin is present in live bodies and exhibits vasoconstricting action, it is expected to be an endogenous factor involved in the regulation of the circulatory system, and may be associated with hypertension, cardiovascular diseases such as myocardial infarction, and renal diseases such as acute renal failure.
  • Endothelin antagonists are described, for example, in U.S. Pat. No. 5,773,414; IP Pat. Publ. 3130299/1991, EP 457,195; EP 460,679; and EP 552,489.
  • a new endothelin B receptor for identifying endothelin receptor antagonists is described in U.S. Pat. No. 5,773,223.
  • ACE angiotensin-converting enzyme
  • ACE inhibitors have functional class III heart failure.
  • ACE inhibitors An alternative to ACE inhibitors is represented by specific ATI receptor antagonists.
  • Clinical studies are planned to compare the efficacy of these two modalities in the treatment of cardiovascular and renal disease.
  • animal model data suggests that the ACE/Ang II pathway, while clearly involved in cardiac hypertrophy, is not the only, or even the primary pathway active in this role.
  • Mouse genetic "knockout" models have been made to test individual components of the pathway. In one such model, the primary cardiac receptor for Ang II, AT sub 1A, has been genetically deleted; these mice do not develop hypertrophy when Ang II is given experimentally (confirming the basic success of the model in eliminating hypertrophy secondary to Ang II).
  • tlirombolytic agents e.g., streptokinase, urokinase, and in particular tissue plasminogen activator (t-PA) have significantly increased the survival of patients who suffered myocardial infarction.
  • t-PA tissue plasminogen activator
  • t-PA may also be administered as a single bolus, although due to its relatively short half-life, it is better suited for infusion therapy. Tebbe et al, Am. J. Cardiol.. 64: 448-453 (1989).
  • TNK t-PA a T103N, Nl 17Q, KHRR(296-299)AAAA t-PA variant, Keyt et al, Proc. Natl. Acad. Sci. USA.91: 3670-3674 ( 1994)
  • TNK t-PA a T103N, Nl 17Q, KHRR(296-299)AAAA t-PA variant, Keyt et al, Proc. Natl. Acad. Sci. USA.91: 3670-3674 ( 1994)
  • the long-term prognosis of patient survival depends greatly on the post-infarction monitoring and treatment of the patients, which should include monitoring and treatment of cardiac hypertrophy.
  • FGF basic and acidic fibroblast growth factors
  • PD-ECGF platelet-derived endofhelial cell growth factor
  • VEGF vascular endothelial growth factor
  • hVEGF human VEGF
  • hVEGF-related proteins Several additional cDNAs were identified in human cDNA libraries that encode 121-, 189-, and 206-amino acid isoforms of hVEGF (also collectively referred to as hVEGF-related proteins).
  • the 121-amino acid protein differs from hVEGF by virtue of the deletion of the 44 amino acids between residues 116 and 159 in hVEGF.
  • the 189-amino acid protein differs from hVEGF by virtue of the insertion of 24 amino acids at residue 116 in hVEGF, and apparently is identical to human vascular permeability factor (hVPF).
  • the 206-amino acid protein differs from hVEGF by virtue of an insertion of 41 amino acids at residue 116 in hVEGF. Houck et al. , Mol. Endocrin..5: 1806 (1991); Ferrara et al., J. Cell. Biochem..47: 211 (1991); Ferrara et al, Endocrine Reviews, 13: 18 (1992); Keck et al, Science. 246: 1309 (1989); Connolly et al, J. Biol.
  • angiogenesis which involves the formation of new blood vessels from preexisting endothelium, is implicated in tlie pathogenesis of a variety of disorders. These include solid tumors and metastasis, atherosclerosis, retrolental fibroplasia, hemangiomas, chronic inflammation, intraocular neovascular syndromes such as proliferative retinopathies, e.g. , diabetic retinopathy, age-related macular degeneration (AMD), neovascular glaucoma, immune rejection of transplanted corneal tissue and other tissues, rheumatoid arthritis, and psoriasis. Folkman etal. J. Biol. Chem..267: 10931-10934 (1992): Klagsbrun etal. Annu. Rev. Physiol..53: 217-
  • Garner A. "Vascular diseases", In: Pathobiology of Ocular Disease. A Dynamic Approach, Garner A., Klintworth GK, eds., 2nd Edition (Marcel Dekker, NY, 1994), pp 1625-1710.
  • angiogenesis appears to be crucial for the transition from hyperplasia to neoplasia, and for providing nourishment for the growth and metastasis of the tumor.
  • Folkman et al. Nature, 339: 58 (1989).
  • the neovascularization allows the tumor cells to acquire a growth advantage and proliferative autonomy compared to the normal cells.
  • a tumor usually begins as a single aberrant cell which can proliferate only to a size of a few cubic millimeters due to the distance from available capillary beds, and it can stay 'dormant' without further growth and dissemination for a long period of time.
  • VEGF has been shown to be a key mediator of neovascularization associated with tumors and intraocular disorders.
  • Ferrara et al. Endocr. Rev., supra.
  • the VEGF mRNA is overexpressed by the majority of human tumors examined. Berkman et al, J. Clin. Invest., 91: 153-159 (1993); Brown et al, Human Pathol., 26: 86-91 (1995); Brown e ⁇ /., Cancer Res., 53: 4727-4735 (1993); Matternetal, Brit. J. Cancer.73: 931-934 (1996); Dvorak et al, Am. J. Pathol.. 146: 1029-1039 (1995).
  • VEGF vascular endothelial growth factor
  • concentration levels of VEGF in eye fluids are highly correlated to the presence of active proliferation of blood vessels in patients with diabetic and other ischemia-related retinopathies.
  • Aiello et al N. Engl. J. Med.. 331: 1480-1487 (1994).
  • recent studies have demonstrated the localization of VEGF in choroidal neovascular membranes in patients affected by AMD. Lopez et al, Invest. Ophthalmol. Vis. Sci..37: 855-868 (1996).
  • Anti-VEGF neutralizing antibodies suppress the growth of a variety of human tumor cell lines hi nude mice
  • CTGF connective tissue growth factor
  • TGF- ⁇ transforming growth factor beta
  • vascular IBP-like growth factor WO 96/17931
  • nov normally arrested in adult kidney cells, which was found to be overexpressed in myeloblastosis-associated- virus-type- 1 -induced nephroblastomas. Joloit et al. Mol. Cell. Biol.. 12: 10-21 (1992).
  • the expression of these immediate-early genes acts as "third messengers" in the cascade of events triggered by growth factors. It is also thought that they are needed to integrate and coordinate complex biological processes, such as differentiation and wound healing in which cell proliferation is a common event.
  • IGFBPs insulin-like growth factor binding proteins
  • IGF insulin-like growth factor
  • vascular endothelial cell growth and angiogenesis In view of the role of vascular endothelial cell growth and angiogenesis in many diseases and disorders, it is desirable to have a means of reducing or inhibiting one or more of the biological effects causing these processes. It is also desirable to have a means of assaying for the presence of pathogenic polypeptides in normal and diseased conditions, and especially cancer. Further, in a specific aspect, as there is no generally applicable therapy for the treatment of cardiac hypertrophy, the identification of factors that can prevent or reduce cardiac myocyte hypertrophy is of primary importance in the development of new therapeutic strategies to inhibit pathophysiological cardiac growth. Wllage there are several treatment modalities for various cardiovascular and oncologic disorders, there is still a need for additional therapeutic approaches.
  • the present invention provides compositions and methods for modulating (e.g., promoting or inhibiting) angiogenesis and/or cardiovascularization in mammals.
  • the present invention is based on the identification of compounds (i.e., proteins) that test positive in various cardiovascular assays that test modulation (e.g., promotion or inhibition) of certain biological activities.
  • the compounds are believed to be useful drugs and/or drug components for the diagnosis and/or treatment (including prevention and amelioration) of disorders where such effects are desired, such as the promotion or inhibition of angiogenesis, inhibition or stimulation of vascular endothelial cell growth, stimulation of growth or proliferation of vascular endothelial cells, inhibition of tumor growth, inhibition of angiogenesis-dependent tissue growth, stimulation of angiogenesis-dependent tissue growth, inhibition of cardiac hypertrophy and stimulation of cardiac hypertrophy, e.g., for the treatment of congestive heart failure.
  • compositions and methods of the invention provide for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of angiogenesis-related disorders, for monitoring tlie efficacy of compounds in clinical trials and for identifying subjects who may be predisposed to such angiogenic-related disorders.
  • the present invention provides a composition comprising a PRO polypeptide, an agonist or antagonist thereof, or an anti-PRO antibody in admixture with a pharmaceutically acceptable carrier.
  • the composition comprises a therapeutically effective amount of the polypeptide, agonist, antagonist or antibody.
  • the composition comprises a further active ingredient, namely, a cardiovascular, endothelial or angiogenic agent or an angiostatic agent, preferably an angiogenic or angiostatic agent.
  • the composition is sterile.
  • the PRO polypeptide, agonist, antagonist or antibody may be administered in the form of a liquid pharmaceutical formulation, which may be preserved to achieve extended storage stability.
  • Preserved liquid pharmaceutical formulations might contain multiple doses of PRO polypeptide, agonist, antagonist or antibody, and might, therefore, be suitable for repeated use.
  • the composition comprises an antibody
  • the antibody is a monoclonal antibody, an antibody fragment, a humanized antibody, or a single-chain antibody.
  • the present invention provides a method for preparing such a composition useful for the treatment of a cardiovascular, endothelial or angiogenic disorder comprising admixing a therapeutically effective amount of a PRO polypeptide, agonist, antagonist or antibody with a pharmaceutically acceptable carrier.
  • the present invention provides an article of manufacture comprising:
  • composition of matter comprising a PRO polypeptide or agonist or antagonist thereof;
  • the present invention provides a method for identifying an agonist of a PRO polypeptide comprising:
  • the present invention provides a method for identifying an agonist of a PRO polypeptide comprising:
  • the invention provides a method for identifying a compound that inhibits the activity of a PRO polypeptide comprising contacting a test compound with a PRO polypeptide under conditions and for a time sufficient to allow the test compound and polypeptide to interact and determining whether the activity of the PRO polypeptide is inhibited.
  • either the test compound or the PRO polypeptide is immobilized on a solid support.
  • the non-immobilized component carries a detectable label. In a preferred aspect, this method comprises the steps of:
  • test compound (b) determining the induction of said cellular response to determine if the test compound is an effective antagonist.
  • this process comprises the steps of:
  • the invention provides a method for identifying a compound that inhibits the expression of a PRO polypeptide in cells that normally expresses the polypeptide, wherein the method comprises contacting the cells with a test compound and determining whether the expression of the PRO polypeptide is inhibited. In a preferred aspect, this method comprises the steps of:
  • the invention provides a compound that inhibits the expression of a PRO polypeptide, such as a compound that is identified by the methods set forth above.
  • Another aspect of the present invention is directed to an agonist or an antagonist of a PRO polypeptide which may optionally be identified by the methods described above.
  • the invention provides an isolated antibody that binds a PRO polypeptide.
  • the antibody is a monoclonal antibody, which preferably has non-human complementarity-determining-region (CDR) residues and human framework-region (FR) residues.
  • CDR non-human complementarity-determining-region
  • FR human framework-region
  • the antibody may be labeled and may be immobilized on a solid support.
  • the antibody is an antibody fragment, a single-chain antibody, or a humanized antibody.
  • the antibody specifically binds to the polypeptide.
  • the present invention provides a method for diagnosing a disease or susceptibility to a disease which is related to a mutation in a PRO polypeptide-encoding nucleic acid sequence comprising determining the presence or absence of said mutation in the PRO polypeptide nucleic acid sequence, wherein the presence or absence of said mutation is indicative of the presence of said disease or susceptibility to said disease.
  • the invention provides a method of diagnosing a cardiovascular, endothelial or angiogenic disorder in a mammal which comprises analyzing the level of expression of a gene encoding a PRO polypeptide (a) in a test sample of tissue cells obtained from said mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower expression level in the test sample as compared to the control sample is indicative of the presence of a cardiovascular, endothelial or angiogenic disorder in said mammal.
  • the expression of a gene encoding a PRO polypeptide may optionally be accomplished by measuring the level of mRNA or the polypeptide in the test sample as compared to the control sample.
  • the present invention provides a method of diagnosing a cardiovascular, endothelial or angiogenic disorder in a mammal which comprises detecting the presence or absence of a PRO polypeptide in a test sample of tissue cells obtained from said mammal, wherein the presence or absence of said PRO polypeptide in said test sample is indicative of the presence of a cardiovascular, endothelial or angiogenic disorder in said mammal.
  • the invention provides a method of diagnosing a cardiovascular, endothelial or angiogenic disorder in a mammal comprising (a) contacting an anti-PRO antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the antibody and the PRO polypeptide in the test sample, wherein the formation of said complex is indicative of the presence of a cardiovascular, endothelial or angiogenic disorder in the mammal.
  • the detection may be qualitative or quantitative, and may be performed in comparison with monitoring the complex formation in a control sample of known normal tissue cells of the same cell type.
  • a larger or smaller quantity of complexes formed in the test sample indicates the presence of a cardiovascular, endothelial or angiogenic dysfunction in the mammal from which the test tissue cells were obtained.
  • the antibody preferably carries a detectable label. Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art.
  • the test sample is usually obtained from an individual suspected to have a cardiovascular, endothelial or angiogenic disorder.
  • the invention provides a method for determining the presence of a PRO polypeptide in a sample comprising exposing a sample suspected of containing the PRO polypeptide to an anti-PRO antibody and determining binding of said antibody to a component of said sample.
  • the sample comprises a cell suspected of containing the PRO polypeptide and the antibody binds to the cell.
  • the antibody is preferably detectably labeled and or bound to a solid support.
  • the invention provides a cardiovascular, endothelial or angiogenic disorder diagnostic kit comprising an anti-PRO antibody and a carrier in suitable packaging.
  • kit further comprises instructions for using said antibody to detect the presence of tlie PRO polypeptide.
  • the carrier is a buffer, for example.
  • the cardiovascular, endothelial or angiogenic disorder is cancer.
  • the present invention provides a method for treating a cardiovascular, endothelial or angiogenic disorder in a mammal comprising administering to the mammal an effective amount of a PRO polypeptide.
  • the disorder is cardiac hypertrophy, trauma such as wounds or burns, or a type of cancer.
  • the mammal is further exposed to angioplasty or a drug that treats cardiovascular, endothelial or angiogenic disorders such as ACE inhibitors or chemotherapeutic agents if the cardiovascular, endothelial or angiogenic disorder is a type of cancer.
  • tl e mammal is human, preferably one who is at risk of developing cardiac hypertrophy and more preferably has suffered myocardial infarction.
  • the cardiac hypertrophy is characterized by the presence of an elevated level of PGF 2 ⁇ .
  • the cardiac hypertrophy may be induced by myocardial infarction, wherein preferably the administration of the PRO polypeptide is initiated within 48 hours, more preferably within 24 hours, following myocardial infarction.
  • the cardiovascular, endothelial or angiogenic disorder is cardiac hypertrophy and said PRO polypeptide is administered together with a cardiovascular, endothelial or angiogenic agent.
  • the preferred cardiovascular, endothelial or angiogenic agent for this purpose is selected from the group consisting of an antihypertensive drug, an ACE inhibitor, an endothelin receptor antagonist and a thrombolytic agent. If a thrombolytic agent is administered, preferably the PRO polypeptide is administered following administration of such agent. More preferably, the thrombolytic agent is recombinant human tissue plasminogen activator.
  • the cardiovascular, endothelial or angiogenic disorder is cardiac hypertrophy and the PRO polypeptide is administered following primary angioplasty for the treatment of acute myocardial infarction, preferably wherein the mammal is further exposed to angioplasty or a cardiovascular, endothelial, or angiogenic agent.
  • the cardiovascular, endothelial or angiogenic disorder is a cancer and the PRO polypeptide is administered in combination with a chemotherapeutic agent, a growth inhibitory agent or a cytotoxic agent.
  • the invention provides a method for treating a cardiovascular, endothelial or angiogenic disorder hi a mammal comprising administering to the mammal an effective amount of a PRO polypeptide agonist, antagonist or anti-PRO antibody.
  • the cardiovascular, endothelial or angiogenic disorder is cardiac hypertrophy, trauma, a cancer, or age-related macular degeneration. Also preferred is where the mammal is human, and where an effective amount of an angiogenic or angiostatic agent is administered in conjunction with the agonist, antagonist or anti-PRO antibody.
  • the invention provides a method for treating a cardiovascular, endothelial or angiogenic disorder in a mammal that suffers therefrom comprising administering to the mammal a nucleic acid molecule that codes for either (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide or (c) an antagonist of a PRO polypeptide, wherein said agonist or antagonist may be an anti-PRO antibody.
  • the mammal is human.
  • the gene is administered via ex vivo gene therapy.
  • the gene is comprised within a vector, more preferably an adenoviral, adeno-associated viral, lentiviral, or retroviral vector.
  • the invention provides a recombinant retroviral particle comprising a retroviral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide, or (c) an antagonist polypeptide of a PRO polypeptide, and a signal sequence for cellular secretion of the polypeptide, wherein the retroviral vector is in association with retroviral structural proteins.
  • the signal sequence is from a mammal, such as from a native PRO polypeptide.
  • the invention supplies an ex vivo producer cell comprising a nucleic acid construct that expresses retroviral structural proteins and also comprises a retroviral vector consisting essentially of a promoter, nucleic acid encoding (a) a PRO polypeptide, (b) an agonist polypeptide of a PRO polypeptide or
  • the invention provides a method for inhibiting endothelial cell growth in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or
  • an antagonist of a PRO polypeptide wherein endothelial cell growth hi said mammal is inhibited, and wherein said agonist or antagonist may be an anti-PRO antibody.
  • the mammal is human and the endothelial cell growth is associated with a tumor or a retinal disorder.
  • the invention provides a method for stimulating endothelial cell growth in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or (c) an antagonist of a PRO polypeptide, wherein endothelial cell growth in said mammal is stimulated, and wherein said agonist or antagonist may be an anti-PRO antibody.
  • the mammal is human.
  • the invention provides a method for inhibiting cardiac hypertrophy in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or
  • an antagonist of a PRO polypeptide wherein cardiac hypertrophy in said mammal is inhibited, and wherein said agonist or antagonist may be an anti-PRO antibody.
  • the mammal is human and the cardiac hypertrophy has been induced by myocardial infarction.
  • the invention provides a method for stimulating cardiac hypertrophy in a mammal comprising administering to the mammal (a) a PRO polypeptide, (b) an agonist of a PRO polypeptide, or
  • an antagonist of a PRO polypeptide wherem cardiac hypertrophy in said mammal is stimulated, and wherein said agonist or antagonist may be an anti-PRO antibody.
  • the mammal is human who suffers from congestive heart failure.
  • the invention provides a mediod for inhibiting angiogenesis induced by a PRO polypeptide in a mammal comprising administering a therapeutically effective amount of an anti-PRO antibody to the mammal.
  • tlie mammal is a human, and more preferably the mammal has a tumor or a retinal disorder.
  • the invention provides a method for stimulating angiogenesis induced by a
  • PRO polypeptide in a mammal comprising administering a therapeutically effective amount of a PRO polypeptide to tlie mammal.
  • the mammal is a human, and more preferably angiogenesis would promote tissue regeneration or wound healing.
  • the invention provides a method for modulating (e.g. , ⁇ ihibiting or stimulating) endothelial cell growth in a mammal comprising administering to the mammal a PR021, PRO 181, PRO205,
  • PR0214 PR0221, PR0229, PR0231, PR0238, PR0241, PR0247, PR0256, PR0258, PR0263, PR0265, PR0295, PR0321, PR0322, PR0337, PR0363, PR0365, PR0444, PR0533, PR0697, PRO720, PR0725, PR0771, PR0788, PR0791, PR0819, PR0827, PR0828, PR0836, PR0846, PR0865, PRO1005, PRO1006, PRO1007, PRO1025, PRO1029, PRO1054, PRO1071, PRO1075, PRO1079, PRO1080, PR01114, PROH31, PR01155, PRO1160, PR01184, PR01186, PRO1190, PR01192, PR01195, PR01244, PR01272, PR01273,
  • the invention provides a method for modulating (e.g. , inhibiting or stimulating) smooth muscle cell growth in a mammal comprising administering to the mammal a PRO 162, PRO 181, PRO 182, PR0195, PRO204, PR0221, PRO230, PR0256, PR0258, PR0533, PR0697, PR0725, PR0738, PR0826, PR0836,PR0840,PR0846,PR0865,PR0982,PR01025,PR01029,PR01071,PR01080,PR01083,PR01134,
  • the invention provides a method for modulating (e.g., inducing or reducing) cardiac hypertrophy in a mammal comprising administering to the mammal a PR021 polypeptide, agonist or antagonist thereof, wherein cardiac hypertrophy in said mammal is modulated.
  • the invention provides a method for modulating (e.g. , inducing or reducing) endothelial cell apoptosis in a mammal comprising administering to the mammal a PRO4302 polypeptide, agonist or antagonist thereof, wherein cardiac hypertrophy in said mammal is modulated.
  • the invention provides a method for modulating (e. g. , stimulating or inhibiting) angiogenesis in a mammal comprising administering a therapeutically effective amount of a PRO 1376 or PRO 1449 polypeptide, agonist or antagonist thereof to the mammal, wherein said angiogenesis is modulated.
  • the invention provides a method for modulating (e.g., inducing or reducing) angiogenesis by modulating (e.g., inducing or reducing) endothelial cell tube formation in a mammal comprising administering to the mammal a PR0178, PR0195, PR0228, PRO301, PRO302, PR0532, PR0724, PRO730, PRO734,PRO793,PRO871,PRO938,PRO1012 ; PRO1120,PRO1139,PRO1198,PRO1287,PRO1361,PRO1864,
  • the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.
  • the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of tlie DNA molecule of (a).
  • the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA as disclosed herein, tlie coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane PRO polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).
  • the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
  • nucleic acid sequence identity 94%, 95%, 96%, 97% or 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein, or (b) the complement of the DNA molecule of (a).
  • Another aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.
  • Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes.
  • nucleic acid fragments are usually at least about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, 400, 450, 500, 600, 700 or 800 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein hi this context the term "about” means the referenced nucleotide sequence length plus or minus 10% of that referenced length.
  • novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise a binding site for an anti-PRO antibody.
  • the invention provides an isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides an isolated PRO polypeptide comprising an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%o, 97% or 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.
  • the invention provides an isolated PRO polypeptide comprising an amino acid sequence having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,
  • the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and that is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described.
  • Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.
  • Another aspect of the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated.
  • Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.
  • the invention provides agonists and antagonists of a native PRO polypeptide as defined herein.
  • the agonist or antagonist is an anti-PRO antibody or a small molecule.
  • the invention provides a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide.
  • the PRO polypeptide is a native PRO polypeptide.
  • the invention provides a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier.
  • the carrier is a pharmaceutically acceptable carrier.
  • Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for tlie preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.
  • the invention provides vectors comprising DNA encoding any of the herein described polypeptides.
  • Host cells comprising any such vector are also provided.
  • tl e host cells may be CHO cells, E. coli, yeast, or Baculovirus-infected insect cells.
  • a process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.
  • the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence.
  • Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.
  • the invention provides an antibody which specifically binds to any of the above or below described polypeptides.
  • the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.
  • the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences.
  • Figure 1 shows a nucleotide sequence (SEQ ID NO: 1) of a native sequence PR0181 cDNA, wherein SEQ ID NO:l is a clone designated herein as "DNA23330-1390".
  • Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:l shown in Figure 1.
  • Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PR0178 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA23339-1130".
  • Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:
  • Figure 5 shows a nucleotide sequence (SEQ ED NO:5) of a native sequence PR0444 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA26846-1397".
  • Figure 6 shows the amino acid sequence (SEQ ID NO: 6) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5.
  • Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a native sequence PRO 195 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA26847-1395".
  • Figure 8 shows the amino acid sequence (SEQ ID NO:8) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.
  • Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a native sequence PROl 82 cDNA, wherein SEQ
  • ID NO:9 is a clone designated herein as "DNA27865-1091".
  • Figure 10 shows the amino acid sequence (SEQ ID NO: 10) derived from the coding sequence of SEQ ID NO:9 shown in Figure 9.
  • Figure 11 shows a nucleotide sequence (SEQ JJD NO: 11) of a native sequence PRO205 cDNA, wherein SEQ ID NO: 11 is a clone designated herein as "DNA30868-1156".
  • Figure 12 shows the amino acid sequence (SEQ ID NO: 12) derived from tlie coding sequence of SEQ ID NO: 11 shown in Figure 11.
  • Figure 13 shows a nucleotide sequence (SEQ ID NO: 13) of a native sequence PRO204 cDNA, wherein SEQ ID NO: 13 is a clone designated herein as "DNA30871-1157".
  • Figure 14 shows the amino acid sequence (SEQ ID NO: 14) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13.
  • Figure 15 shows a nucleotide sequence (SEQ ID NO: 15) ofa native sequence PR01873 cDNA, wherein
  • SEQ ID NO: 15 is a clone designated herein as "DNA30880”.
  • Figure 16 shows the amino acid sequence (SEQ ID NO: 16) derived from the coding sequence of SEQ ID NO: 15 shown in Figure 15.
  • Figure 17 shows a nucleotide sequence (SEQ ID NO: 17) of a native sequence PR0214 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA32286-1191".
  • Figure 18 shows the amino acid sequence (SEQ ID NO: 18) derived from the coding sequence of SEQ ID NO: 17 shown in Figure 17.
  • Figure 19 shows a nucleotide sequence (SEQ ID NO:19) of a native sequence PR0221 cDNA, wherein SEQ ID NO: 19 is a clone designated herein as "DNA33089-1132".
  • Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO:
  • Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a native sequence PR0228 cDNA, wherem SEQ ID NO:21 is a clone designated herein as "DNA33092-1202".
  • Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.
  • Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a native sequence PR0229 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA33100-1159".
  • Figure 24 shows the amino acid sequence (SEQ ID NO:24) derived from tlie coding sequence of SEQ ID NO:23 shown in Figure 23.
  • Figure 25 shows a nucleotide sequence (SEQ ID NO:25) ofa native sequence PRO230 cDNA, wherein
  • SEQ ID NO:25 is a clone designated herein as "DNA33223-1136".
  • Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ ID NO:25 shown in Figure 25.
  • Figure 27 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PR07223 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA34385".
  • Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27.
  • Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a native sequence PR0241 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA34392-1170".
  • Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.
  • Figure 31 shows a nucleotide sequence (SEQ ID NO:31) of a native sequence PR0263 cDNA, wherein
  • SEQ ID NO:31 is a clone designated herein as "DNA34431-1177".
  • Figure 32 shows the amino acid sequence (SEQ ID NO:32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.
  • Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a native sequence PR0321 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA34433-1308".
  • Figure 34 shows the amino acid sequence (SEQ ID NO: 34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.
  • Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a native sequence PR0231 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA34434-1139".
  • Figure 36 shows tlie amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:
  • Figure 37 shows a nucleotide sequence (SEQ ID NO:37) of a native sequence PR0238 cDNA, wherem SEQ ID N0:37 is a clone designated herein as "DNA35600-1162".
  • Figure 38 shows the amino acid sequence (SEQ ID NO: 38) derived from the coding sequence of SEQ ID NO:37 shown in Figure 37.
  • Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a native sequence PR0247 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA35673-1201".
  • Figure 40 shows the amino acid sequence (SEQ ID NO:40) derived from the coding sequence of SEQ ID NO:39 shown in Figure 39.
  • Figure 41 shows a nucleotide sequence (SEQ ID NO:41) of a native sequence PR0256 cDNA, wherein
  • SEQ ID NO:41 is a clone designated herein as "DNA35880-1160".
  • Figure 42 shows the amino acid sequence (SEQ ID NO:42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 41.
  • Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a native sequence PR0258 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA35918-1174".
  • Figure 44 shows the amino acid sequence (SEQ ID NO:44) derived from the coding sequence of SEQ ID NO:43 shown in Figure 43.
  • Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a native sequence PR0265 cDNA, wherein SEQ ID NO:45 is a clone designated herein as "DNA36350-1158".
  • Figure 46 shows the amino acid sequence (SEQ ID NO:46) derived from the coding sequence of SEQ ID NO:
  • Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a native sequence PR021 cDNA, wherein SEQ ID NO:47 is a clone designated herein as "DNA36638-1056".
  • Figure 48 shows the amino acid sequence (SEQ ID NO:48) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.
  • Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a native sequence PR0295 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA38268-1188".
  • Figure 50 shows the ammo acid sequence (SEQ ID NO:50) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.
  • Figure 51 shows a nucleotide sequence (SEQ ID NO:51) of a native sequence PRO302 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA40370-1217".
  • Figure 52 shows the amino acid sequence (SEQ ID NO:52) derived from the coding sequence of SEQ ID NO:52
  • Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a native sequence PRO301 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA40628-1216".
  • Figure 54 shows the amino acid sequence (SEQ ID NO:54) derived from the coding sequence of SEQ ID NO:53 shown in Figure 53.
  • Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a native sequence PR0337 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA43316-1237".
  • Figure 56 shows the amino acid sequence (SEQ ID NO:56) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.
  • Figure 57 shows a nucleotide sequence (SEQ ID NO:57) ofa native sequence PR07248 cDNA, wherein
  • SEQ ID NO:57 is a clone designated herein as "DNA44195".
  • Figure 58 shows the amino acid sequence (SEQ ID O:58) derived from the coding sequence of SEQ ID NO:57 shown in Figure 57.
  • Figure 59 shows a nucleotide sequence (SEQ ID NO:59) of a native sequence PR0846 cDNA, wherein SEQ ID NO:59 is a clone designated herein as "DNA44196-1353".
  • Figure 60 shows the amino acid sequence (SEQ ID NO:60) derived from the coding sequence of SEQ ID NO:59 shown in Figure 59.
  • Figure 61 shows a nucleotide sequence (SEQ ID NO:61) ofa native sequence PR01864 cDNA, wherein SEQ ID NO:61 is a clone designated herein as "DNA45409-2511".
  • Figure 62 shows the amino acid sequence (SEQ ID NO : 62) derived from the coding sequence of SEQ ID NO:
  • Figure 63 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PR0363 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "DNA45419-1252".
  • Figure 64 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ED NO:63 shown in Figure 63.
  • Figure 65 shows a nucleotide sequence (SEQ ID NO:65) of a native sequence PRO730 cDNA, wherein SEQ ID NO:65 is a clone designated herein as "DNA45624-1400".
  • Figure 66 shows the amino acid sequence (SEQ ID NO:66) derived from the coding sequence of SEQ ID NO:65 shown in Figure 65.
  • Figure 67 shows a nucleotide sequence (SEQ ID NO:67) of a native sequence PR0365 cDNA, wherein SEQ ID N0:67 is a clone designated herein as "DNA46777-1253".
  • Figure 68 shows the amino acid sequence (SEQ ID NO:68) derived from the coding sequence of SEQ ID NO:
  • Figure 69 shows a nucleotide sequence (SEQ JD NO: 69) ofa native sequence PR0532 cDNA, wherein SEQ ID N0:69 is a clone designated herein as "DNA48335".
  • Figure 70 shows tlie amino acid sequence (SEQ ID NO:70) derived from the coding sequence of SEQ ID NO:69 shown in Figure 69.
  • Figure 71 shows a nucleotide sequence (SEQ ID NO:71) of a native sequence PR0322 cDNA, wherein SEQ ID NO:71 is a clone designated herein as "DNA48336-1309".
  • Figure 72 shows the amino acid sequence (SEQ ID NO:72) derived from tlie coding sequence of SEQ ID NO:71 shown in Figure 71.
  • Figure 73 shows a nucleotide sequence (SEQ ID NO:73) ofa native sequence PROl 120 cDNA, wherein
  • SEQ ID NO:73 is a clone designated herein as "DNA48606-1479".
  • Figure 74 shows the amino acid sequence (SEQ ID NO:74) derived from the coding sequence of SEQ ID NO:73 shown in Figure 73.
  • Figure 75 shows a nucleotide sequence (SEQ ID NO:75) of a native sequence PR07261 cDNA, wherein SEQ ID NO:75 is a clone designated herein as "DNA49149".
  • Figure 76 shows the amino acid sequence (SEQ ID NO:76) derived from the coding sequence of SEQ JD NO:75 shown in Figure 75.
  • Figure 77 shows a nucleotide sequence (SEQ ID NO:77) of a native sequence PR0533 cDNA, wherein SEQ ID NO:77 is a clone designated herein as "DNA49435-1219".
  • Figure 78 shows the amino acid sequence (SEQ ID NO:78) derived from the coding sequence of SEQ ID NO:
  • Figure 79 shows a nucleotide sequence (SEQ ID NO:79) of a native sequence PR0724 cDNA, wherein SEQ ID N0:79 is a clone designated herein as "DNA49631-1328".
  • Figure 80 shows the amino acid sequence (SEQ ID NO: 80) derived from the coding sequence of SEQ ID NO:79 shown in Figure 79.
  • Figure 81 shows a nucleotide sequence (SEQ ID NO:81) of a native sequence PR0734 cDNA, wherein SEQ JD NO:81 is a clone designated herein as "DNA49817".
  • Figure 82 shows the amino acid sequence (SEQ ID NO:82) derived from the coding sequence of SEQ ID NO:81 shown in Figure 81.
  • Figure 83 shows a nucleotide sequence (SEQ ID NO:83) of a native sequence PR0771 cDNA, wherein
  • SEQ ID NO:83 is a clone designated herein as "DNA49829-1346".
  • Figure 84 shows tlie amino acid sequence (SEQ ID NO: 84) derived from the coding sequence of SEQ ID NO:83 shown in Figure 83.
  • Figure 85 shows a nucleotide sequence (SEQ ID NO:85) of a native sequence PRO2010 cDNA, wherein SEQ ID NO:85 is a clone designated herein as "DNA50792".
  • Figure 86 shows the amino acid sequence (SEQ ID NO:86) derived from the coding sequence of SEQ ID NO:85 shown in Figure 85.
  • Figure 87 shows a nucleotide sequence (SEQ ID NO:87) of a native sequence PR0871 cDNA, wherein SEQ ID N0:87 is a clone designated herein as "DNA50919-1361".
  • Figure 88 shows the amino acid sequence (SEQ ID NO:88) derived from the coding sequence of SEQ ID NO:87 shown in Figure 87.
  • Figure 89 shows a nucleotide sequence (SEQ ID NO:89) of a native sequence PR0697 cDNA, wherein
  • SEQ ID NO:89 is a clone designated herein as "DNA50920-1325”.
  • Figure 90 shows the amino acid sequence (SEQ ID NO:90) derived from the coding sequence of SEQ ID NO:89 shown in Figure 89.
  • Figure 91 shows a nucleotide sequence (SEQ ID NO:91) of anative sequence PRO1083 cDNA, wherein SEQ ID NO:91 is a clone designated herein as "DNA50921-1458".
  • Figure 92 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:91 shown in Figure 91.
  • Figure 93 shows a nucleotide sequence (SEQ ID NO:93) ofa native sequence PR0725 cDNA, wherein SEQ ID NO:93 is a clone designated herein as "DNA52758-1399".
  • Figure 94 shows the amino acid sequence (SEQ ID NO:94) derived from the coding sequence of SEQ ID NO:94
  • Figure 95 shows a nucleotide sequence (SEQ ID NO:95) of a native sequence PRO720 cDNA, wherein SEQ ID NO:95 is a clone designated herein as "DNA53517-1366-1".
  • Figure 96 shows the amino acid sequence (SEQ ID NO:96) derived from the coding sequence of SEQ ID NO:95 shown in Figure 95.
  • Figure 97 shows a nucleotide sequence (SEQ ID NO:97) of a native sequence PR0738 cDNA, wherein SEQ ID NO:97 is a clone designated herein as "DNA53915-1258".
  • Figure 98 shows the amino acid sequence (SEQ JD NO:98) derived from the coding sequence of SEQ ID NO:97 shown in Figure 97.
  • Figure 99 shows a nucleotide sequence (SEQ ID NO:99) of a native sequence PR0865 cDNA, wherein
  • SEQ ID NO:99 is a clone designated herein as "DNA53974-1401".
  • Figure 100 shows the amino acid sequence (SEQ JD NO:100) derived from the coding sequence of SEQ ID NO:99 shown in Figure 99.
  • Figure 101 shows a nucleotide sequence (SEQ ID NO: 101) of a native sequence PRO840 cDNA, wherein SEQ ID NO:101 is a clone designated herein as "DNA53987-1438".
  • Figure 102 shows the amino acid sequence (SEQ JD NO: 102) derived from the coding sequence of SEQ JD NO:101 shown in Figure 101.
  • Figure 103 shows anucleotide sequence (SEQ JD NO: 103) of anative sequence PRO 1080 cDNA, wherein SEQ ID NO: 103 is a clone designated herein as "DNA56047-1456".
  • Figure 104 shows the amino acid sequence (SEQ ID NO:104) derived from the coding sequence of SEQ ID NO: 103 shown in Figure 103.
  • Figure 105 shows a nucleotide sequence (SEQ ID NO: 105) of a native sequence PRO 1079 cDNA, wherein
  • SEQ ID NO:105 is a clone designated herein as "DNA56050-1455".
  • Figure 106 shows the amino acid sequence (SEQ ID NO:106) derived from the coding sequence of SEQ ID NO: 105 shown in Figure 105.
  • Figure 107 shows a nucleotide sequence (SEQ ID NO: 107) of a native sequence PR0793 cDNA, wherein SEQ JD NO: 107 is a clone designated herein as "DNA56110- 1437" .
  • Figure 108 shows the amino acid sequence (SEQ ID NO:108) derived from the coding sequence of SEQ ID NO: 107 shown in Figure 107.
  • Figure 109 shows a nucleotide sequence (SEQ ID NO: 109) of a native sequence PR0788 cDNA, wherein SEQ ID NO: 109 is a clone designated herein as "DNA56405-1357”.
  • Figure 110 shows the amino acid sequence (SEQ ID NO: 110) derived from the coding sequence of SEQ
  • Figure 111 shows a nucleotide sequence (SEQ JD NO: 111) of a native sequence PR0938 cDNA, wherein SEQ ID NO:l 11 is a clone designated herein as "DNA56433-1406".
  • Figure 112 shows the amino acid sequence (SEQ ID NO:l 12) derived from the coding sequence of SEQ ID NO:l 11 shown in Figure 111.
  • Figure 113 shows a nucleotide sequence (SEQ JD NO : 113) of a native sequence PRO 1012 cDNA, wherein SEQ ID NO:l 13 is a clone designated herein as "DNA56439-1376".
  • Figure 114 shows the amino acid sequence (SEQ ID NO: 114) derived from the coding sequence of SEQ ID NO: 113 shown in Figure 113.
  • Figure 115 shows a nucleotide sequence (SEQ ID NO: 115) ofa native sequence PRO 1477 cDNA, wherein
  • SEQ ID NO:l 15 is a clone designated herein as "DNA56529-1647".
  • Figure 116 shows the amino acid sequence (SEQ ID NO:l 16) derived from the coding sequence of SEQ JD NO: 115 shown in Figure 115.
  • Figure 117 shows a nucleotide sequence (SEQ JD NO: 117) of anative sequence PROl 134cDNA, wherein SEQ JD NO:l 17 is a clone designated herein as "DNA56865-1491".
  • Figure 118 shows the amino acid sequence (SEQ ID NO : 118) derived from the coding sequence of SEQ ID NO: 117 shown in Figure 117.
  • Figure 119 shows a nucleotide sequence (SEQ ID NO: 119) of a native sequence PRO 162 cDNA, wherein SEQ ID NO: 119 is a clone designated herein as "DNA56965-1356".
  • Figure 120 shows the amino acid sequence (SEQ JD NO:120) derived from the coding sequence of SEQ
  • Figure 121 shows a nucleotide sequence (SEQ ID NO: 121 ) of a native sequence PRO 1114 cDNA, wherein SEQ JD NO: 121 is a clone designated herein as "DNA57033-1403-1".
  • Figure 122 shows the amino acid sequence (SEQ ID NO: 122) derived from the coding sequence of SEQ ID NO:121 shown in Figure 121.
  • Figure 123 shows a nucleotide sequence (SEQ JD NO: 123) of a native sequence PR0828 cDNA, wherein SEQ ID NO: 123 is a clone designated herein as "DNA57037-1444".
  • Figure 124 shows the amino acid sequence (SEQ ID NO: 124) derived from the coding sequence of SEQ ID NO: 123 shown in Figure 123.
  • Figure 125 shows a nucleotide sequence (SEQ ID NO: 125) of anative sequence PR0827 cDNA, wherein SEQ ID NO:125 is a clone designated herein as "DNA57039-1402".
  • Figure 126 shows the amino acid sequence (SEQ ID NO:126) derived from tlie coding sequence of SEQ ID NO:126
  • Figure 127 shows a nucleotide sequence (SEQ ID NO: 127) of a native sequence PRO 1075 cDNA, wherein SEQ ID NO:127 is a clone designated herein as "DNA57689-1385".
  • Figure 128 shows the amino acid sequence (SEQ ID NO: 128) derived from the coding sequence of SEQ ID NO: 127 shown in Figure 127.
  • Figure 129 shows a nucleotide sequence (SEQ ID NO: 129) of a native sequence PRO 1007 cDNA, wherein SEQ JD NO: 129 is a clone designated herein as "DNA57690-1374".
  • Figure 130 shows the amino acid sequence (SEQ ID NO:130) derived from the coding sequence of SEQ ID NO: 129 shown in Figure 129.
  • Figure 131 shows a nucleotide sequence (SEQ ID NO: 131) ofa native sequence PR0826 cDNA, wherein
  • SEQ ID NO: 131 is a clone designated herein as "DNA57694-1341".
  • Figure 132 shows the amino acid sequence (SEQ ID NO:132) derived from the coding sequence of SEQ ID NO: 131 shown in Figure 131.
  • Figure 133 shows a nucleotide sequence (SEQ ID NO: 133) of a native sequence PR0819 cDNA, wherein SEQ JD NO:132 is a clone designated herein as "DNA57695-1340".
  • Figure 134 shows the amino acid sequence (SEQ ID NO:134) derived from the coding sequence of SEQ JD NO: 133 shown in Figure 133.
  • Figure 135 shows a nucleotide sequence (SEQ JD NO: 135) of anative sequence PRO1006 cDNA, wherein SEQ ID NO:135 is a clone designated herein as "DNA57699-1412".
  • Figure 136 shows the amino acid sequence (SEQ ID NO:136) derived from the coding sequence of SEQ
  • Figure 137 shows a nucleotide sequence (SEQ ID NO: 137) ofa native sequence PR0982 cDNA, wherein SEQ ID NO:137 is a clone designated herein as "DNA57700-1408".
  • Figure 138 shows the amino acid sequence (SEQ ED N0:138) derived from the coding sequence of SEQ ID N0:137 shown in Figure 137.
  • Figure 139 shows a nucleotide sequence (SEQ ID NO : 139) of a native sequence PRO 1005 cDNA, wherein SEQ JD NO:139 is a clone designated herein as "DNA57708-1411".
  • Figure 140 shows the amino acid sequence (SEQ JD NO: 140) derived from the coding sequence of SEQ ID NO: 139 shown in Figure 139.
  • Figure 141 shows a nucleotide sequence (SEQ ID NO: 141) of a native sequence PR0791 cDNA, wherein SEQ ID NO:141 is a clone designated herein as "DNA57838-1337".
  • Figure 142 shows the amino acid sequence (SEQ ID NO: 142) derived from the coding sequence of SEQ
  • JD NO:141 shown in Figure 141 JD NO:141 shown in Figure 141.
  • Figure 143 showsanucleotidesequence (SEQIDNO:143) ofanativesequencePRO1071 cDNA, wherein SEQ ID NO: 143 is a clone designated herein as "DNA58847-1383".
  • Figure 144 shows the amino acid sequence (SEQ ID NO: 144) derived from the coding sequence of SEQ ID NO: 143 shown hi Figure 43.
  • Figure 145 shows anucleotide sequence (SEQ ID NO: 145) of anative sequence PRO 1415 cDNA, wherein SEQ ID NO: 145 is a clone designated herein as "DNA58852-1637".
  • Figure 146 shows tl e amino acid sequence (SEQ ID NO:146) derived from the coding sequence of SEQ ID NO: 145 shown in Figure 145.
  • Figure 147 shows a nucleotide sequence (SEQ ID NO: 147) ofa native sequence PRO 1054 cDNA, wherein
  • SEQ ID NO:147 is a clone designated herein as "DNA58853-1423".
  • Figure 148 shows the amino acid sequence (SEQ ID NO: 148) derived from the coding sequence of SEQ ID NO: 147 shown in Figure 147.
  • Figure 149 shows anucleotide sequence (SEQ ID NO: 149) of anative sequence PRO 1411 cDNA, wherein SEQ ID NO: 149 is a clone designated herein as "DNA59212-1627".
  • Figure 150 shows the amino acid sequence (SEQ ID NO: 150) derived from the coding sequence of SEQ ID NO: 149 shown in Figure 149.
  • Figure 151 shows a nucleotide sequence (SEQ JD NO: 151) of a native sequence PRO 1184 cDNA, wherein SEQ ID NO:151 is a clone designated herein as "DNA59220-1514".
  • Figure 152 shows the amino acid sequence (SEQ ID NO: 152) derived from the coding sequence of SEQ
  • Figure 153 shows a nucleotide sequence (SEQ ID NO: 153) of a native sequence PRO 1029 cDNA, wherein SEQ ID NO:153 is a clone designated herein as "DNA59493-1420".
  • Figure 154 shows the amino acid sequence (SEQ ID NO: 154) derived from the coding sequence of SEQ ID NO: 153 shown in Figure 153.
  • Figure 155 shows anucleotide sequence (SEQ ID NO: 155) of anative sequence PROl 139 cDNA, wherein SEQ ID NO: 155 is a clone designated herein as "DNA59497-1496".
  • Figure 156 shows the amino acid sequence (SEQ ID NO:156) derived from the coding sequence of SEQ ID NO: 155 shown in Figure 155.
  • Figure 157 shows a nucleotide sequence (SEQ JD NO: 157) ofa native sequence PRO 1190 cDNA, wherein
  • SEQ JD NO: 157 is a clone designated herein as "DNA59586-1520".
  • Figure 158 shows the amino acid sequence (SEQ ID NO: 158) derived from the coding sequence of SEQ ID N0:157 shown in Figure 157.
  • Figure 159 shows a nucleotide sequence (SEQ ID NO: 159) of a native sequence PRO 1309 cDNA, wherein SEQ ID NO: 159 is a clone designated herein as "DNA59588-1571".
  • Figure 160 shows the amino acid sequence (SEQ ID NO: 160) derived from the coding sequence of SEQ ID NO: 159 shown in Figure 159.
  • Figure 161 shows anucleotide sequence (SEQ IDNO:161) of anative sequence PR0836 cDNA, wherein SEQ ID NO: 161 is a clone designated herein as "DNA59620-1463".
  • Figure 162 shows the amino acid sequence (SEQ ID NO: 162) derived from the coding sequence of SEQ ID NO:161 shown in Figure 161.
  • Figure 163 shows anucleotide sequence (SEQ ID NO:163) ofanativesequencePRO1025 cDNA, wherein
  • SEQ JD NO:163 is a clone designated herein as "DNA59622-1334".
  • Figure 164 shows the amino acid sequence (SEQ ID NO: 164) derived from the coding sequence of SEQ JD NO:163 shown in Figure 163.
  • Figure 165 shows a nucleotide sequence (SEQ ID NO: 165) of a native sequence PRO 1131 cDNA, wherein SEQ ID NO: 165 is a clone designated herein as "DNA59777-1480".
  • Figure 166 shows the amino acid sequence (SEQ JD NO: 166) derived from the coding sequence of SEQ ID NO: 165 shown in Figure 165.
  • Figure 167 shows a nucleotide sequence (SEQ DD NO: 167) of a native sequence PRO 1182 cDNA, wherein SEQ ID NO: 167 is a clone designated herein as "DNA59848-1512".
  • Figure 168 shows the amino acid sequence (SEQ ID NO: 168) derived from the coding sequence of SEQ
  • Figure 169 shows a nucleotide sequence (SEQ JD NO : 169) of a native sequence PRO 1155 cDNA, wherein SEQ ID NO:169 is a clone designated herein as "DNA59849- 1504".
  • Figure 170 shows the amino acid sequence (SEQ ID NO: 170) derived from the coding sequence of SEQ ID NO: 169 shown in Figure 169.
  • Figure 171 shows a nucleotide sequence (SEQ JD NO: 171) of a native sequence PRO 1186 cDNA, wherein SEQ ID NO: 171 is a clone designated herein as "DNA60621-1516".
  • Figure 172 shows the amino acid sequence (SEQ ID NO: 172) derived from the coding sequence of SEQ ID NO:171 shown in Figure 171.
  • Figure 173 shows anucleotide sequence (SEQ ID NO:173) ofanative sequencePROH98 cDNA, wherein
  • SEQ ID NO: 173 is a clone designated herein as "DNA60622-1525".
  • Figure 174 shows the amino acid sequence (SEQ ID NO: 174) derived from the coding sequence of SEQ ID NO: 173 shown in Figure 173.
  • Figure 175 shows a nucleotide sequence (SEQ ED NO: 175) of a native sequence PRO 1265 cDNA, wherein SEQ ID NO: 175 is a clone designated herein as "DNA60764-1533".
  • Figure 176 shows the amino acid sequence (SEQ JD NO: 176) derived from the coding sequence of SEQ ID NO: 175 shown hi Figure 175.
  • Figure 177 shows a nucleotide sequence (SEQ ED NO: 177) of anative sequence PR01361 cDNA, wherein SEQ ID NO: 177 is a clone designated herein as "DNA60783-1611".
  • Figure 178 shows the amino acid sequence (SEQ ID NO: 178) derived from the coding sequence of SEQ ID NO: 177 shown in Figure 177.
  • Figure 179 shows anucleotide sequence (SEQ ID NO: 179) of anative sequence PR01287 cDNA, wherein
  • SEQ ID NO:179 is a clone designated herein as "DNA61755-1554".
  • Figure 180 shows the amino acid sequence (SEQ ID NO:180) derived from the coding sequence of SEQ ID NO: 179 shown in Figure 179.
  • Figure 181 shows a nucleotide sequence (SEQ ID NO : 181 ) of a native sequence PRO 1308 cDNA, wherein SEQ ID NO:181 is a clone designated herein as "DNA62306-1570".
  • Figure 182 shows the amino acid sequence (SEQ ID NO: 182) derived from tlie coding sequence of SEQ JD NO:181 shown in Figure 181.
  • Figure 183 shows a nucleotide sequence (SEQ ID NO: 183) of anative sequence PR04313 cDNA, wherein SEQ ID NO:183 is a clone designated herein as "DNA62312-2558".
  • Figure 184 shows the amino acid sequence (SEQ ID NO: 184) derived from the coding sequence of SEQ
  • Figure 185 shows a nucleotide sequence (SEQ ID NO: 185) of a native sequence PRO 1192 cDNA, wherein SEQ ID NO:185 is a clone designated herein as "DNA62814-1521".
  • Figure 186 shows the amino acid sequence (SEQ ID NO: 186) derived from the coding sequence of SEQ ID NO: 185 shown in Figure 185.
  • Figure 187 shows a nucleotide sequence (SEQ ID NO: 187) of a native sequence PRO 1160 cDNA, wherein SEQ ID NO:187 is a clone designated herein as "DNA62872-1509".
  • Figure 188 shows the ammo acid sequence (SEQ ID NO: 188) derived from the coding sequence of SEQ ID NO:187 shown in Figure 187.
  • Figure 189 shows a nucleotide sequence (SEQ ID NO: 189) of anative sequence PRO 1244 cDNA, wherein
  • SEQ ID NO:189 is a clone designated herein as "DNA64883-1526".
  • Figure 190 shows the amino acid sequence (SEQ ID NO: 190) derived from the coding sequence of SEQ ID NO:189 shown in Figure 189.
  • Figure 191 shows a nucleotide sequence (SEQ ID NO: 191 ) of a native sequence PRO 1356 cDNA, wherein SEQ ID NO:191 is a clone designated herein as "DNA64886-1601".
  • Figure 192 shows the amino acid sequence (SEQ ID NO:192) derived from the coding sequence of SEQ ID NO:191 shown in Figure 191.
  • Figure 193 shows a nucleotide sequence (SEQ ID NO: 193) of anative sequence PRO 1274 cDNA, wherein SEQ ID NO:193 is a clone designated herein as "DNA64889-1541".
  • Figure 194 shows the amino acid sequence (SEQ ID NO : 194) derived from the coding sequence of SEQ
  • Figure 195 shows a nucleotide sequence (SEQ JD NO: 195) of a native sequence PRO 1272 cDNA, wherein SEQ JD NO: 195 is a clone designated herein as "DNA64896-1539".
  • Figure 196 shows the amino acid sequence (SEQ ID NO: 196) derived from the coding sequence of SEQ ID NO:195 shown in Figure 195.
  • Figure 197 shows a nucleotide sequence (SEQ ID NO : 197) of a native sequence PRO 1412 cDNA, wherein SEQ ID NO:197 is a clone designated herein as "DNA64897-1628".
  • Figure 198 shows the amino acid sequence (SEQ ID NO: 198) derived from the coding sequence of SEQ ID NO:197 shown in Figure 197.
  • Figure 199 shows a nucleotide sequence (SEQ ID NO : 199) ofa native sequence PRO 1286 cDNA, wherein SEQ ID NO: 199 is a clone designated herein as "DNA64903-1553".
  • Figure 200 shows tlie amino acid sequence (SEQ ID NO:200) derived from the coding sequence of SEQ ID NO:
  • Figure 201 shows a nucleotide sequence (SEQ ID NO:201 ) of a native sequence PRO 1347 cDNA, wherein SEQ ID NO:201 is a clone designated herein as "DNA64950-1590".
  • Figure 202 shows the amino acid sequence (SEQ ID NO:202) derived from tlie coding sequence of SEQ ID NO:201 shown in Figure 201.
  • Figure 203 shows anucleotide sequence (SEQ IDNO:203) of anative sequence PRO 1273 cDNA, wherein SEQ JD NO:203 is a clone designated herein as "DNA65402-1540".
  • Figure 204 shows the amino acid sequence (SEQ ID NO:204) derived from the coding sequence of SEQ ID NO:203 shown in Figure 203.
  • Figure 205 shows a nucleotide sequence (SEQ ID NO:205) ofa native sequence PRO 1283 cDNA, wherein
  • SEQ ID NO:205 is a clone designated herein as "DNA65404-1551".
  • Figure 206 shows the amino acid sequence (SEQ ID NO:206) derived from the coding sequence of SEQ JD NO:205 shown in Figure 205.
  • Figure 207 shows a nucleotide sequence (SEQ ID NO:207) of a native sequence PRO 1279 cDNA, wherein SEQ ID NO:207 is a clone designated herein as "DNA65405- 1547".
  • Figure 208 shows the amino acid sequence (SEQ ID NO:208) derived from the coding sequence of SEQ ID NO:207 shown in Figure 207.
  • Figure 209 shows a nucleotide sequence (SEQ ID NO:209) of a native sequence PRO 1306 cDNA, wherein SEQ ID NO:209 is a clone designated herein as "DNA65410-1569".
  • Figure 210 shows the amino acid sequence (SEQ JD NO:210) derived from the coding sequence of SEQ
  • Figure 211 shows a nucleotide sequence (SEQ JD NO:211 ) of a native sequence PRO 1195 cDNA, wherein SEQ ID NO:211 is a clone designated herein as "DNA65412-1523".
  • Figure 212 shows the amino acid sequence (SEQ JD NO:212) derived from the coding sequence of SEQ ID NO:211 shown in Figure 211.
  • Figure 213 shows a nucleotide sequence (SEQ JD NO:213) of a native sequence PR04995 cDNA, wherein SEQ ID NO:213 is a clone designated herein as "DNA66307-2661".
  • Figure 214 shows the amino acid sequence (SEQ ID NO:214) derived from the coding sequence of SEQ ID NO:213 shown in Figure 213.
  • Figure 215 shows a nucleotide sequence (SEQ ID NO:215) of a native sequence PRO 1382 cDNA, wherein SEQ ID NO:215 is a clone designated herein as "DNA66526-1616".
  • Figure 216 shows the amino acid sequence (SEQ ID NO:216) derived from the coding sequence of SEQ
  • Figure217 shows anucleotide sequence (SEQ ID NO:217) of anative sequence PR01325 cDNA, wherein SEQ ID NO:217 is a clone designated herein as "DNA66659-1593".
  • Figure 218 shows the amino acid sequence (SEQ ID NO:218) derived from the coding sequence of SEQ ID NO:217 shown in Figure 217.
  • Figure 219 shows a nucleotide sequence (SEQ ID NO:219) of a native sequence PRO 1329 cDNA, wherein SEQ ID NO:219 is a clone designated herein as "DNA66660-1585".
  • Figure 220 shows the amino acid sequence (SEQ ID NO:220) derived from tlie coding sequence of SEQ JD NO:219 shown in Figure 219.
  • Figure 221 shows a nucleotide sequence (SEQ ID NO:221) ofa native sequence PRO 1338 cDNA, wherein
  • SEQ ID NO:221 is a clone designated herein as "DNA66667-1596".
  • Figure 222 shows the amino acid sequence (SEQ ID NO:222) derived from the coding sequence of SEQ ID NO:221 shown in Figure 221.
  • Figure 223 shows anucleotide sequence (SEQ ID NO:223) of anative sequence PRO 1337 cDNA, wherein SEQ ID NO:223 is a clone designated herein as "DNA66672-1586".
  • Figure 224 shows the amino acid sequence (SEQ ID NO:224) derived from the coding sequence of SEQ ID NO:223 shown in Figure 223.
  • Figure 225 shows a nucleotide sequence (SEQ ID NO:225) ofa native sequence PR01343 cDNA, wherein SEQ ID NO:225 is a clone designated herein as "DNA66675-1587".
  • Figure 226 shows the amino acid sequence (SEQ ID NO:226) derived from the coding sequence of SEQ
  • Figure 227 shows anucleotide sequence (SEQ ID NO:227) of anative sequence PR01376 cDNA, wherein SEQ ID NO:227 is a clone designated herein as "DNA67300-1605".
  • Figure 228 shows the amino acid sequence (SEQ ID NO:228) derived from the coding sequence of SEQ ID NO:227 shown in Figure 227.
  • Figure 229 shows anucleotide sequence (SEQ JD NO:229) of anative sequence PR01434 cDNA, wherein SEQ JD NO:229 is a clone designated herein as "DNA68818-2536".
  • Figure 230 shows the amino acid sequence (SEQ ID NO:230) derived from the coding sequence of SEQ JD NO:229 shown in Figure 229.
  • Figure 231 shows a nucleotide sequence (SEQ ID NO:231) ofa native sequence PR03579 cDNA, wherein
  • SEQ ID NO:231 is a clone designated herein as "DNA68862-2546".
  • Figure 232 shows the amino acid sequence (SEQ ID NO:232) derived from the coding sequence of SEQ ID NO:231 shown in Figure 231.
  • Figure 233 shows anucleotide sequence (SEQ ID NO:233) of anative sequence PR01387 cDNA, wherein SEQ ID NO:233 is a clone designated herein as "DNA68872- 1620".
  • Figure 234 shows the amino acid sequence (SEQ ID N0:234) derived from the coding sequence of SEQ ID NO:233 shown in Figure 233.
  • Figure 235 shows a nucleotide sequence (SEQ ID NO :235) of a native sequence PRO 1419 cDNA, wherein SEQ ID NO:235 is a clone designated herein as "DNA71290-1630".
  • Figure 236 shows the amino acid sequence (SEQ ID NO:236) derived from the coding sequence of SEQ JD NO:235 shown in Figure 235.
  • Figure 237 shows anucleotide sequence (SEQ ID NO:237) ofa native sequence PRO 1488 cDNA, wherein
  • SEQ ID NO:237 is a clone designated herein as "DNA73736-1657”.
  • Figure 238 shows the amino acid sequence (SEQ JD NO:238) derived from the coding sequence of SEQ ID NO:237 shown in Figure 237.
  • Figure 239 shows a nucleotide sequence (SEQ ID NO:239) of anative sequence PR01474 cDNA, wherein SEQ ID NO:239 is a clone designated herein as "DNA73739-1645".
  • Figure 240 shows tlie amino acid sequence (SEQ ID NO:240) derived from the coding sequence of SEQ ID NO:239 shown in Figure 239.
  • Figure 241 shows anucleotide sequence (SEQ ID NO:241) of anative sequence PRO1508 cDNA, wherein SEQ ID NO:241 is a clone designated herein as "DNA73742- 1662".
  • Figure 242 shows the amino acid sequence (SEQ JD NO:242) derived from the coding sequence of SEQ
  • Figure 243 shows a nucleotide sequence (SEQ ID NO:243) of a native sequence PRO 1754 cDNA, wherem SEQ JD NO:243 is a clone designated herein as "DNA76385-1692".
  • Figure 244 shows the amino acid sequence (SEQ ID NO:244) derived from the coding sequence of SEQ ID NO:243 shown in Figure 243.
  • Figure 245 shows a nucleotide sequence (SEQ ID NO:245) o a native sequence PROl 550 cDNA, wherein SEQ ID NO:245 is a clone designated herein as "DNA76393-1664".
  • Figure 246 shows the amino acid sequence (SEQ JD NO:246) derived from the coding sequence of SEQ ID NO:245 shown in Figure 245.
  • Figure 247 shows a nucleotide sequence (SEQ ID NO:247) ofa native sequence PROl 758 cDNA, wherein
  • SEQ JD NO:247 is a clone designated herein as "DNA76399-1700".
  • Figure 248 shows the amino acid sequence (SEQ ID NO:248) derived from tl e coding sequence of SEQ ID NO:247 shown in Figure 247.
  • Figure 249 shows a nucleotide sequence (SEQ JD NO:249) of a native sequence PRO 1917 cDNA, wherein SEQ ID NO:249 is a clone designated herein as "DNA76400-2528".
  • Figure 250 shows the amino acid sequence (SEQ JD NO:250) derived from the coding sequence of SEQ ID NO:249 shown in Figure 249.
  • Figure 251 shows a nucleotide sequence (SEQ ED N0:251) ofa native sequence PRO 1787 cDNA, wherein SEQ JD NO:251 is a clone designated herein as "DNA76510-2504".
  • Figure 252 shows the amino acid sequence (SEQ ID NO:252) derived from the coding sequence of SEQ JD NO:251 shown in Figure 251.
  • Figure 253 shows anucleotide sequence (SEQ J NO:253) of anative sequence PRO 1556 cDNA, wherein
  • SEQ ID NO:253 is a clone designated herein as "DNA76529-1666".
  • Figure 254 shows the amino acid sequence (SEQ JD NO:254) derived from the coding sequence of SEQ ID NO:253 shown in Figure 253.
  • Figure 255 shows anucleotide sequence (SEQ EDNO:255) of anative sequence PRO 1760 cDNA, wherein SEQ ID NO:255 is a clone designated herein as "DNA76532-1702".
  • Figure 256 shows tlie amino acid sequence (SEQ ID NO:256) derived from the coding sequence of SEQ JD NO:255 shown in Figure 255.
  • Figure 257 shows a nucleotide sequence (SEQ ID NO:257) ofa native sequence PRO 1567 cDNA, wherein SEQ ID NO:257 is a clone designated herein as "DNA76541-1675".
  • Figure 258 shows the amino acid sequence (SEQ ID NO:258) derived from tlie coding sequence of SEQ
  • JD NO:257 shown in Figure 257.
  • Figure 259 shows a nucleotide sequence (SEQ ID NO:259) of a native sequence PRO 1600 cDNA, wherein SEQ ID NO:259 is a clone designated herein as "DNA77503-1686".
  • Figure 260 shows the amino acid sequence (SEQ ID NO:260) derived from the coding sequence of SEQ ID NO:259 shown in Figure 259.
  • Figure 261 shows anucleotide sequence (SEQ ID O:261) of anative sequence PROl 868 cDNA, wherein SEQ ID NO:261 is a clone designated herein as "DNA77624-2515".
  • Figure 262 shows the amino acid sequence (SEQ JD NO:262) derived from the coding sequence of SEQ ID NO:261 shown in Figure 261.
  • Figure 263 shows a nucleotide sequence (SEQ ID NO:263) ofa native sequence PRO 1890 cDNA, wherein
  • SEQ ID NO:263 is a clone designated herein as "DNA79230-2525".
  • Figure 264 shows the amino acid sequence (SEQ JD NO:264) derived from the coding sequence of SEQ ID NO:263 shown in Figure 263.
  • Figure 265 shows a nucleotide sequence (SEQ ID NO:265) of a native sequence PROl 887 cDNA, wherein SEQ ID NO:265 is a clone designated herein as "DNA79862-2522".
  • Figure 266 shows the amino acid sequence (SEQ JD NO:265) derived from tlie coding sequence of SEQ ID NO:265 shown in Figure 265.
  • Figure 267 shows a nucleotide sequence (SEQ ID NO:267) of anative sequence PR04353 cDNA, wherein SEQ JD NO:267 is a clone designated herein as "DNA80145-2594".
  • Figure 268 shows the amino acid sequence (SEQ ED NO:268) derived from the coding sequence of SEQ
  • JD NO:267 shown in Figure 267.
  • Figure 269 shows a nucleotide sequence (SEQ ID NO:269) of a native sequence PRO 1782 cDNA, wherein SEQ ID NO:269 is a clone designated herein as "DNA80899-2501".
  • Figure 270 shows the amino acid sequence (SEQ ID NO:270) derived from the coding sequence of SEQ ID NO:269 shown in Figure 269.
  • Figure 271 shows a nucleotide sequence (SEQ ID NO:271 ) of a native sequence PRO 1928 cDNA, wherein SEQ ID NO:271 is a clone designated herein as "DNA81754-2532".
  • Figure 272 shows the amino acid sequence (SEQ ID NO:272) derived from the coding sequence of SEQ ID NO:271 shown in Figure 271.
  • Figure 273 shows a nucleotide sequence (SEQ ID NO:273) of anative sequence PRO 1865 cDNA, wherein SEQ ID NO:273 is a clone designated herein as "DNA81757-2512".
  • Figure 274 shows the amino acid sequence (SEQ JD NO:274) derived from the coding sequence of SEQ
  • JD NO:273 shown in Figure 273.
  • Figure 275 shows a nucleotide sequence (SEQ JD NO:275) of a native sequence PR04341 cDNA, wherein SEQ ID NO:275 is a clone designated herein as "DNA81761-2583".
  • Figure 276 shows the amino acid sequence (SEQ ID NO:276) derived from the coding sequence of SEQ ID NO:275 shown in Figure 275.
  • Figure 277 shows a nucleotide sequence (SEQ ID NO:277) of a native sequence PR06714 cDNA, wherein SEQ ID NO:277 is a clone designated herein as "DNA82358-2738".
  • Figure 278 shows the amino acid sequence (SEQ ID NO:278) derived from the coding sequence of SEQ JD NO:277 shown in Figure 277.
  • Figure 279 shows anucleotide sequence (SEQ JD NO:279) of anative sequence PR05723 cDNA, wherein
  • SEQ ID NO:279 is a clone designated herein as "DNA82361".
  • Figure 280 shows the amino acid sequence (SEQ ID NO:280) derived from the coding sequence of SEQ JD NO:279 shown in Figure 279.
  • Figure 281 shows anucleotide sequence (SEQ IDNO:281) of anative sequence PR03438 cDNA, wherein SEQ ID NO:281 is a clone designated herein as "DNA82364-2538".
  • Figure 282 shows the amino acid sequence (SEQ ID NO:282) derived from the coding sequence of SEQ ID NO:281 shown in Figure 281.
  • Figure 283 shows a nucleotide sequence (SEQ ID NO:283) of a native sequence PRO6071 cDNA, wherein SEQ ID NO:283 is a clone designated herein as "DNA82403-2959".
  • Figure 284 shows the amino acid sequence (SEQ ID NO:284) derived from the coding sequence of SEQ
  • Figure 285 shows a nucleotide sequence (SEQ JD NO:285) of a native sequence PRO 1801 cDNA, wherein SEQ JD NO:285 is a clone designated herein as "DNA83500-2506".
  • Figure 286 shows the amino acid sequence (SEQ ID NO:286) derived from the coding sequence of SEQ ID NO:285 shown in Figure 285.
  • Figure 287 shows a nucleotide sequence (SEQ ID NO:287) ofa native sequence PR04324 cDNA, wherein SEQ ID NO:287 is a clone designated herein as "DNA83560-2569".
  • Figure 288 shows the amino acid sequence (SEQ ID NO:288) derived from the coding sequence of SEQ ID NO:287 shown in Figure 287.
  • Figure 289 shows a nucleotide sequence (SEQ ID NO:289) of a native sequence PR04333 cDNA, wherein SEQ JD NO:289 is a clone designated herein as "DNA84210-2576".
  • Figure 290 shows the amino acid sequence (SEQ ID NO:290) derived from the coding sequence of SEQ
  • Figure 291 shows a nucleotide sequence (SEQ ID NO:291) of a native sequence PRO4405 cDNA, wherein SEQ ID NO:291 is a clone designated herein as "DNA84920-2614".
  • Figure 292 shows the amino acid sequence (SEQ ID NO:292) derived from the coding sequence of SEQ ID NO:291 shown in Figure 291.
  • Figure 293 shows a nucleotide sequence (SEQ ID NO:293) of a native sequence PR04356 cDNA, wherem SEQ JD NO:293 is a clone designated herein as "DNA86576-2595".
  • Figure 294 shows the amino acid sequence (SEQ ID NO:294) derived from the coding sequence of SEQ JD NO:293 shown in Figure 293.
  • Figure 295 shows anucleotide sequence (SEQ JD NO:295) of a native sequence PR03444 cDNA, wherein
  • SEQ ID NO:295 is a clone designated herein as "DNA87997".
  • Figure 296 shows the amino acid sequence (SEQ ID NO:296) derived from the coding sequence of SEQ JD NO:295 shown in Figure 295.
  • Figure 297 shows a nucleotide sequence (SEQ ID NO:297) of a native sequence PR04302 cDNA, wherein SEQ JD NO:297 is a clone designated herein as "DNA92218-2554".
  • Figure 298 shows the amino acid sequence (SEQ ID NO:298) derived from the coding sequence of SEQ ID NO:297 shown in Figure 297.
  • Figure 299 shows a nucleotide sequence (SEQ ID NO:299) of a native sequence PR04371 cDNA, wherein SEQ ID NO:299 is a clone designated herein as "DNA92233-2599".
  • Figure 300 shows the amino acid sequence (SEQ ID NO:300) derived from the coding sequence of SEQ
  • Figure 301 shows a nucleotide sequence (SEQ JD NO :301 ) of a native sequence PR04354 cDNA, wherein .
  • SEQ ID NO:301 is a clone designated herein as "DNA92256-2596".
  • Figure 302 shows the amino acid sequence (SEQ ID NO:302) derived from the coding sequence of SEQ ED NO:301 shown in Figure 301.
  • Figure 303 shows a nucleotide sequence (SEQ IDNO:303) of anative sequence PR05725 cDNA, wherein SEQ ID NO:303 is a clone designated herein as "DNA92265-2669".
  • Figure 304 shows the amino acid sequence (SEQ ID NO:304) derived from the coding sequence of SEQ JD NO:303 shown in Figure 303.
  • Figure 305 shows a nucleotide sequence (SEQ ID NO :305) ofa native sequence PRO4408 cDNA, wherein
  • SEQ ID NO:305 is a clone designated herein as "DNA92274-2617".
  • Figure 306 shows the amino acid sequence (SEQ ID NO:306) derived from the coding sequence of SEQ ED NO:305 shown in Figure 305.
  • Figure 307 shows a nucleotide sequence (SEQ JD NO:307) ofa native sequence PRO9940 cDNA, wherein SEQ ID NO:307 is a clone designated herein as "DNA92282".
  • Figure 308 shows the amino acid sequence (SEQ ID NO:308) derived from the coding sequence of SEQ ID NO:307 shown in Figure 307.
  • Figure 309 shows anucleotide sequence (SEQ ID NO:309) of anative sequence PR05737 cDNA, wherein SEQ JD NO:309 is a clone designated herein as "DNA92929-2534-1".
  • Figure 310 shows the amino acid sequence (SEQ ID NO:310) derived from the coding sequence of SEQ ID NO:309 shown in Figure 309.
  • Figure 311 shows a nucleotide sequence (SEQ JD NO:311) ofa native sequence PR04425 cDNA, wherein
  • SEQ ID NO:311 is a clone designated herein as "DNA93011-2637".
  • Figure 312 shows the amino acid sequence (SEQ ID NO:312) derived from the coding sequence of SEQ JD NO:311 shown in Figure 311.
  • Figure 313 shows a nucleotide sequence (SEQ ID NO:313) of a native sequence PR04345 cDNA, wherein SEQ ID NO:313 is a clone designated herein as "DNA94854-2586".
  • Figure 314 shows the amino acid sequence (SEQ ID NO:314) derived from the coding sequence of SEQ ID NO:313 shown in Figure 313.
  • Figure 315 shows a nucleotide sequence (SEQ ID NO:315) of a native sequence PR04342 cDNA, wherein SEQ ED NO:315 is a clone designated herein as "DNA96787-2534-1".
  • Figure 316 shows the amino acid sequence (SEQ JD NO:316) derived from the coding sequence of SEQ
  • JD NO:315 shown in Figure 315.
  • Figure317 shows anucleotide sequence (SEQ JDNO:317) of anative sequence PR03562 cDNA, wherein SEQ ID NO:317 is a clone designated herein as "DNA96791".
  • Figure 318 shows the amino acid sequence (SEQ ID NO:318) derived from the coding sequence of SEQ ID NO:317 shown in Figure 317.
  • Figure 319 shows anucleotide sequence (SEQ IDNO:319) of anative sequence PR04422 cDNA, wherein SEQ JD NO:319 is a clone designated herein as "DNA96867-2620".
  • Figure 320 shows the amino acid sequence (SEQ JD NO:320) derived from the coding sequence of SEQ JD NO:319 shown in Figure 319.
  • Figure 321 shows a nucleotide sequence (SEQ ID NO:321) ofa native sequence PR05776 cDNA, wherein
  • SEQ JD NO:321 is a clone designated herein as "DNA96872-2674".
  • Figure 322 shows the amino acid sequence (SEQ ID NO:322) derived from the coding sequence of SEQ JD NO:321 shown in Figure 321.
  • Figure 323 shows a nucleotide sequence (SEQ ID NO:323) of a native sequence PRO4430 cDNA, wherein SEQ ID NO:323 is a clone designated herein as "DNA96878-2626".
  • Figure 324 shows the amino acid sequence (SEQ ID NO:324) derived from the coding sequence of SEQ ID NO:323 shown in Figure 323.
  • Figure 325 shows anucleotide sequence (SEQID O:325) of anative sequence PR04499 cDNA, wherein SEQ JD NO:325 is a clone designated herein as "DNA96889-2641".
  • Figure 326 shows the amino acid sequence (SEQ ID NO:326) derived from the coding sequence of SEQ ID NO:325 shown in Figure 325.
  • Figure 327 shows a nucleotide sequence (SEQ JD NO:327) ofa native sequence PRO4503 cDNA, wherein
  • SEQ ID NO:327 is a clone designated herein as "DNA100312-2645".
  • Figure 328 shows tlie amino acid sequence (SEQ JD NO:328) derived from the coding sequence of SEQ ID NO:327 shown in Figure 327.
  • Figure 329 shows a nucleotide sequence (SEQ JD NO:329) of a native sequence PRO 10008 cDNA, wherein SEQ ID NO:329 is a clone designated herein as "DNA101921".
  • Figure 330 shows the amino acid sequence (SEQ ID NO:330) derived from the coding sequence of SEQ ID NO:329 shown in Figure 329.
  • Figure331 shows anucleotide sequence (SEQ ID O:331) of anative sequence PRO5730 cDNA, wherein SEQ ID NO:331 is a clone designated herein as "DNA101926".
  • Figure 332 shows the amino acid sequence (SEQ JD NO:332) derived from tlie coding sequence of SEQ
  • Figure 333 shows a nucleotide sequence (SEQ ID NO:333) of a native sequence PRO6008 cDNA, wherein SEQ ID NO:333 is a clone designated herein as "DNA102844".
  • Figure 334 shows the amino acid sequence (SEQ JD NO:334) derived from the coding sequence of SEQ JD NO:333 shown in Figure 333.
  • Figure 335 shows anucleotide sequence (SEQ ID NO:335) of anative sequence PR04527 cDNA, wherein SEQ ID NO:335 is a clone designated herein as "DNA103197".
  • Figure 336 shows the amino acid sequence (SEQ JD NO:336) derived from the coding sequence of SEQ ID NO:335 shown in Figure 335.
  • Figure 337 shows anucleotide sequence (SEQ ID NO:337) of anative sequence PR04538 cDNA, wherein
  • SEQ ID NO:337 is a clone designated herein as "DNA103208".
  • Figure 338 shows the amino acid sequence (SEQ ID NO:338) derived from the coding sequence of SEQ JD NO-.337 shown hi Figure 337.
  • Figure 339 shows anucleotide sequence (SEQJDNO:339) of anative sequence PR04553 cDNA, wherein SEQ ID NO:339 is a clone designated herein as "DNA103223".
  • Figure 340 shows the amino acid sequence (SEQ ID NO:340) derived from the coding sequence of SEQ ID NO:339 shown in Figure 339.
  • Figure 341 shows anucleotide sequence (SEQ JD NO:341) of anative sequence PRO6006 cDNA, wherein SEQ ID NO:341 is a clone designated herein as "DNA105782-2693".
  • Figure 342 shows the amino acid sequence (SEQ ID NO:342) derived from the coding sequence of SEQ
  • Figure 343 shows a nucleotide sequence (SEQ JD NO:343) of a native sequence PRO6029 cDNA, wherein SEQ ID NO:343 is a clone designated herein as "DNA105849-2704".
  • Figure 344 shows the amino acid sequence (SEQ ID NO:344) derived from the coding sequence of SEQ ID NO:343 shown in Figure 343.
  • Figure 345 shows a nucleotide sequence (SEQ ID NO:345) of a native sequence PR09821 cDNA, wherein SEQ ID NO:345 is a clone designated herein as "DNA108725-2766".
  • Figure 346 shows the amino acid sequence (SEQ ID NO:346) derived from the coding sequence of SEQ ID NO:345 shown in Figure 345.
  • Figure 347 shows anucleotide sequence (SEQ JD NO:347) of anative sequence PRO9820 cDNA, wherein SEQ ID NO:347 is a clone designated herein as "DNA108769-2765".
  • Figure 348 shows the amino acid sequence (SEQ ID NO:348) derived from the coding sequence of SEQ
  • Figure 349 shows a nucleotide sequence (SEQ JD NO:349) of a native sequence PR09771 cDNA, wherein SEQ ID NO:349 is a clone designated herein as "DNA119498-2965".
  • Figure 350 shows the amino acid sequence (SEQ JD NO:350) derived from the coding sequence of SEQ ID NO:349 shown in Figure 349.
  • Figure 351 shows a nucleotide sequence (SEQ ID NO:351 ) of a native sequence PR07436 cDNA, wherein SEQ ID O:351 is a clone designated herein as "DNA119535-2756".
  • Figure 352 shows the amino acid sequence (SEQ ID NO:352) derived from the coding sequence of SEQ ID NO:351 shown in Figure 351.
  • Figure 353 shows a nucleotide sequence (SEQ ID NO:353) of a native sequence PRO10096 cDNA, wherein SEQ JD NO:353 is a clone designated herein as "DNA125185-2806".
  • Figure 354 shows the amino acid sequence (SEQ ID NO:354) derived from the coding sequence of SEQ ID NO:353 shown in Figure 353.
  • Figure 355 shows a nucleotide sequence (SEQ ID NO:355) of a native sequence PRO19670 cDNA, wherein SEQ JD NO:355 is a clone designated herein as "DNA131639-2874".
  • Figure 356 shows the amino acid sequence (SEQ ID NO:356) derived from the coding sequence of SEQ ID NO:355 shown in Figure 355.
  • Figure 357 shows a nucleotide sequence (SEQ ID NO:357) of a native sequence PRO20044 cDNA, wherein SEQ ID NO:357 is a clone designated herein as "DNA139623-2893".
  • Figure 358 shows the amino acid sequence (SEQ JD NO:358) derived from the coding sequence of SEQ
  • Figure 359 shows anucleotide sequence (SEQIDNO:359) of anative sequence PR09873 cDNA, wherein SEQ ID NO:359 is a clone designated herein as "DNA143076-2787".
  • Figure 360 shows the amino acid sequence (SEQ JD NO:360) derived from the coding sequence of SEQ ID NO:359 shown in Figure 359.
  • Figure 361 shows a nucleotide sequence (SEQ JD NO:361) of a native sequence PR021366 cDNA, wherein SEQ JD NO:361 is a clone designated herein as "DNA143276-2975".
  • Figure 362 shows the amino acid sequence (SEQ JD NO:362) derived from the coding sequence of SEQ ID NO:361 shown in Figure 361.
  • Figure 363 shows a nucleotide sequence (SEQ ID NO:363) of a native sequence PRO20040 cDNA, wherein SEQ ID NO:363 is a clone designated herein as "DNA164625-2890".
  • Figure 364 shows the amino acid sequence (SEQ ID NO:364) derived from the coding sequence of SEQ
  • Figure 365 shows a nucleotide sequence (SEQ ID NO:365) of a native sequence PR021184 cDNA, wherein SEQ ID NO:365 is a clone designated herein as "DNA167678-2963".
  • Figure 366 shows the amino acid sequence (SEQ ID NO:366) derived from the coding sequence of SEQ ID NO:365 shown in Figure 365.
  • Figure 367 shows a nucleotide sequence (SEQ ID NO:367) of a native sequence PRO21055 cDNA, wherein SEQ ID NO:367 is a clone designated herein as "DNA170021-2923".
  • Figure 368 shows the amino acid sequence (SEQ JD NO:368) derived from tlie coding sequence of SEQ JD NO:367 shown in Figure 367.
  • Figure 369 shows a nucleotide sequence (SEQ ID NO:369) of a native sequence PR028631 cDNA, wherein SEQ ID NO:369 is a clone designated herein as "DNA170212-3000".
  • Figure 370 shows the amino acid sequence (SEQ ID NO:370) derived from the coding sequence of SEQ ID NO:369 shown in Figure 369.
  • Figure 371 shows a nucleotide sequence (SEQ ID NO:371) of a native sequence PR021384 cDNA, wherein SEQ JD NO:371 is a clone designated herein as "DNA177313-2982".
  • Figure 372 shows the amino acid sequence (SEQ ID NO:372) derived from the coding sequence of SEQ JD NO:371 shown in Figure 371.
  • Figure 373 shows anucleotide sequence (SEQ ID NO:373) of anative sequence PRO 1449 cDNA, wherein SEQ ID NO:373 is a clone designated herein as "DNA64908-1163-1".
  • Figure 374 shows the amino acid sequence (SEQ ID NO:374) derived from the coding sequence of SEQ
  • Figure 375 shows wholemount in situ hybridization results on mouse embryos using a mouse orthologue ofPR01449 wliichhas about 78% amino acid identity with PRO 1449.
  • the results show that PRO 1449 orthologue is expressed in the developing vasculature.
  • the cross-section further shows expression in endothelial cells and progenitors of endothelial cells.
  • Figure 376 shows that a PR01449 orthologue having about 78% amino acid identity with PRO 1449 is expressed in vasculature of many inflamed and diseased tissues, but is very low, or lacking, in normal adult vessels.
  • Figure 377 shows that a PR01449 orthologue having about 78% amino acid identity with PR01449 induces ectopic vessels in the eyes of chicken embryos. 5. Detailed Description of the Invention
  • cardiovascular, endothelial and angiogenic disorder cardiac, endothelial and angiogenic disorder
  • cardiac, endothelial and angiogenic dysfunction cardiac, endothelial or angiogenic disorder
  • cardiovascular, endothelial or angiogenic dysfunction cardiac, endothelial or angiogenic dysfunction
  • cardiac, endothelial or angiogenic dysfunction refers in part to systemic disorders that affect vessels, such as diabetes mellitus, as well as diseases of the vessels themselves, such as of the arteries, capillaries, veins, and/or lymphatics. This would include indications that stimulate angiogenesis and or cardiovascularization, and those that inhibit angiogenesis and/or cardiovascularization.
  • Such disorders include, for example, arterial disease, such as atherosclerosis, hypertension, inflammatory vasculitides, Reynaud's disease and Reynaud's phenomenon, aneurysms, and arterial restenosis; venous and lymphatic disorders such as thrombophlebitis, lymphangitis, and lymphedema; and other vascular disorders such as peripheral vascular disease, cancer such as vascular tumors, e.g.
  • hemangioma capillary and cavernous
  • glomus tumors telangiectasia
  • bacillary angiomatosis hemangioendothelioma
  • angiosarcoma haemangiopericytoma
  • Kaposi's sarcoma lymphangioma
  • lymphangiosarcoma tumor angiogenesis
  • trauma such as wounds, burns, and other injured tissue
  • implant fixation scarring
  • ischemia reperfusion injury rheumatoid arthritis
  • cerebrovascular disease renal diseases such as acute renal failure, and osteoporosis.
  • renal diseases such as acute renal failure, and osteoporosis.
  • “Hypertrophy”, as used herein, is defined as an increase in mass of an organ or structure independent of natural growth that does not involve tumor formation. Hypertrophy of an organ or tissue is due either to an increase in the mass of the individual cells (true hypertrophy), or to an increase in the number of cells making up tlie tissue
  • cardiomy hypertrophy is defined as an increase in mass of the heart, which, in adults, is characterized by an increase in myocyte cell size and contractile protein content without concomitant cell division. ' The character of the stress responsible for inciting the hypertrophy, (e.g., increased preload, increased afterload, loss of myocytes, as in myocardial infarction, or primary depression of contractility), appears to play a critical role in determining tlie nature of the response.
  • the early stage of cardiac hypertrophy is usually characterized mo ⁇ hologically by increases in the size of myofibrils and mitochondria, as well as by enlargement of mitochondria and nuclei. At this stage, while muscle cells are larger than normal, cellular organization is largely preserved. At a more advanced stage of cardiac hypertrophy, there are preferential increases in the size or number of specific organelles, such as mitochondria, and new contractile elements are added in localized areas of the cells, in an irregular manner. Cells subjected to long-standing hypertrophy show more obvious disruptions in cellular organization, including markedly enlarged nuclei with highly lobulated membranes, which displace adjacent myofibrils and cause breakdown of normal Z-band registration.
  • cardiac hypertrophy is used to include all stages of the progression of this condition, characterized by various degrees of structural damage of the heart muscle, regardless of the underlying cardiac disorder. Hence, the term also includes physiological conditions instrumental in the development of cardiac hypertrophy, such as elevated blood pressure, aortic stenosis, or myocardial infarction.
  • Heart failure refers to an abnormality of cardiac function where the heart does not pump blood at the rate needed for the requirements of metabolizing tissues.
  • the heart failure can be caused by a number of factors, including ischemic, congenital, rheumatic, or idiopafhic forms.
  • CHF Congestive heart failure
  • Myocardial infarction generally results from atherosclerosis of the coronary arteries, often with superimposed coronary thrombosis. It may be divided into two major types: transmural infarcts, in which myocardial necrosis involves the full thickness of the ventricular wall, and subendocardial (nontransmural) infarcts, in which the necrosis involves tlie subendocardium, the intramural myocardium, or both, without extending all the way through the ventricular wall to the epicardium. Myocardial infarction is known to cause both a change in hemodynamic effects and an alteration in structure in the damaged and healthy zones of the heart.
  • myocardial infarction reduces the maximum cardiac output and the stroke volume of the heart. Also associated with myocardial infarction is a stimulation of the DNA synthesis occurring in the interstice as well as an increase in the formation of collagen in the areas of the heart not affected.
  • cardiac hypertrophy has long been associated with "hypertension".
  • a characteristic of the ventricle that becomes hypertrophic as a result of chronic pressure overload is an impaired diastolic performance.
  • hypotrophic cardiomyopathy Another complex cardiac disease associated with cardiac hypertrophy is "hypertrophic cardiomyopathy”. This condition is characterized by a great diversity of morphologic, functional, and clinical features (Maron et al, N. Engl. J. Med.. 316: 780-789 (1987); Spirito et al, N. Engl J. Med.. 320: 749-755 (1989); Louie and Edwards,
  • Supravalvular "aortic stenosis” is an inherited vascular disorder characterized by narrowing of the ascending aorta, but other arteries, including tlie pulmonary arteries, may also be affected. Untreated aortic stenosis may lead to increased intracardiac pressure resulting in myocardial hypertrophy and eventually heart failure and death. The pathogenesis of this disorder is not fully understood, but hypertrophy and possibly hype ⁇ lasia of medial smooth muscle are prominent features of this disorder. It has been reported that molecular variants of the elastin gene are involved in the development and pathogenesis of aortic stenosis. U.S. Patent No. 5,650,282 issued July 22, 1997.
  • Valvular regurgitation occurs as a result of heart diseases resulting in disorders of tlie cardiac valves.
  • Various diseases like rheumatic fever, can cause the shrinking or pulling apart of the valve orifice, while other diseases may result in endocarditis, an inflammation of tl e endocardium or lining membrane of the atrioventricular orifices and operation of the heart.
  • Defects such as the narrowing of the valve stenosis or the defective closing of the valve result in an accumulation of blood in the heart cavity or regurgitation of blood past the valve. If uncorrected, prolonged valvular stenosis or insufficiency may result in cardiac hypertrophy and associated damage to the heart muscle, which may eventually necessitate valve replacement.
  • cancer cardiovascular, endothelial and angiogenic disorders, which may or may not be accompanied by cardiac hypertrophy, is encompassed by the present invention.
  • cancer cancer
  • cancer cancer
  • cancer include but are not limited to, carcinoma including adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia.
  • cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's andnon-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer.
  • cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
  • the term is intended to include radioactive isotopes (e.g., 13I I, 125 1, 90 Y, and I86 Re), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof.
  • chemotherapeutic agent is a chemical compound useful in the treatment of cancer.
  • examples of chemotherapeutic agents include alkylating agents, folic acid antagonists, anti-metabolites of nucleic acid metabolism, antibiotics, pyrimidine analogs, 5-fluorouracil, cisplatin, purine nucleosides, amines, amino acids, triazol nucleosides, or corticosteroids.
  • Adriamycin Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Taxol, Toxotere, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see U.S. Pat. No. 4,675, 187), Melphalan, and other related nitrogen mustards. Also included in this definition are hormonal agents that act to regulate or inhibit hormone action on tumors, such as tamoxifen and onapristone.
  • a “growtli-inhibitory agent” when used herein refers to a compound or composition that inhibits growth ofa cell, such as an Wnt-overexpressing cancer cell, either in vitro or in vivo.
  • the growth-inhibitory agent is one which significantly reduces the percentage of malignant cells in S phase.
  • growm-inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce
  • M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, daunorubicin, etoposide, and bleomycin.
  • Those agents that arrest Gl also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer. Mendelsohn and Israel, eds.
  • tumor necrosis factor an antibody capable of inhibiting or neutralizing tlie angiogenic activity of acidic or basic FGF or hepatocyte growth factor (HGF), an antibody capable of inliibiting or neutralizing the coagulant activities of tissue factor, protein C, or protein S (see, WO 91/01753, published 21 February 1991), or an antibody capable of binding to HER2 receptor (WO 89/06692), such as the 4D5 antibody (and functional equivalents thereof) (e.g. , WO 92/22653).
  • TNF tumor necrosis factor
  • HGF hepatocyte growth factor
  • 4D5 antibody and functional equivalents thereof
  • Treatment is an intervention performed with the intention of preventing the development or altering the pathology of a cardiovascular, endothelial, and angiogenic disorder.
  • the concept of treatment is used in the broadest sense, and specifically includes the prevention (prophylaxis), moderation, reduction, and curing of cardiovascular, endothelial, and angiogenic disorders of any stage.
  • treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) or ameliorate a cardiovascular, endothelial, and angiogenic disorder such as hypertrophy.
  • Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
  • the disorder may result from any cause, including idiopathic, cardiotrophic, or myotrophic causes, or ischemia or ischemic insults, such as myocardial infarction.
  • Chronic administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial effect, such as an anti-hypertrophic effect, for an extended period of time.
  • “Mammal” for pu ⁇ oses of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, pigs, etc.
  • the mammal is human.
  • cardiovascular, endothelial or angiogenic agents refers genetically to any drug that acts in treating cardiovascular, endothelial, and angiogenic disorders.
  • cardiovascular agents are those that promote vascular homeostasis by modulating blood pressure, heart rate, heart contractility, and endothelial and smooth muscle biology, all of which factors have a role in cardiovascular disease.
  • angiotensin-II receptor antagonists include angiotensin-II receptor antagonists; endothelin receptor antagonists such as, for example, BOSENTANTM and MOXONODINTM; interferon-gamma (IFN- ⁇ ); des-aspartate-angiotensin I; thrombolytic agents, e.g., streptokinase, urokinase, t-PA, and a t-PA variant specifically designed to have longer half-life and very high fibrin specificity, TNK t-PA (a T103N, Nl 17Q, KHRR(296-299)AAAA t-PA variant, Keyt et al, Proc. Nat Acad. Sci. USA.
  • TNK t-PA a T103N, Nl 17Q, KHRR(296-299)AAAAAA t-PA variant
  • inotropic or hypertensive agents such as digoxigenin and ⁇ -adrenergic receptor blocking agents, e.g., propranolol, timolol, tertalolol, carteolol, nadolol, betaxolol, penbutolol, acetobutolol, atenolol, metoprolol, and carvedilol; angiotensin converting enzyme (ACE) inhibitors, e.g., quinapril, captopril, enalapril, ramipril, benazepril, fosinopril, and lisinopril; diuretics, e.g., chlorotliiazide, hydrochlorothiazide, hydroflumetliazide, methylchlothiazide, benzthiazide, dichlo ⁇ henamide
  • Angiogenic agents and “endothelial agents” are active agents that promote angiogenesis and/or endothelial cell growth, or, if applicable, vasculogenesis. This would include factors that accelerate wound healing, such as growth hormone, insulin-like growth factor-I (IGF-I), VEGF, VIGF, PDGF, epidermal growth factor (EGF), CTGF and members of its family, FGF, and TGF- ⁇ and TGF- ⁇ .
  • IGF-I insulin-like growth factor-I
  • VEGF VEGF
  • VIGF vascular endothelial growth factor
  • PDGF epidermal growth factor
  • CTGF and members of its family
  • FGF and TGF- ⁇ and TGF- ⁇ .
  • Angiostatic agents are active agents that inhibit angiogenesis or vasculogenesis or otherwise inhibit or prevent growth of cancer cells. Examples include antibodies or other antagonists to angiogenic agents as defined above, such as antibodies to VEGF. They additionally include cytotherapeutic agents such as cytotoxic agents, chemotherapeutic agents, growth-inhibitory agents, apoptotic agents, and other agents to treat cancer, such as anti- HER-2, anti-CD20, and other bioactive and organic chemical agents.
  • cytotherapeutic agents such as cytotoxic agents, chemotherapeutic agents, growth-inhibitory agents, apoptotic agents, and other agents to treat cancer, such as anti- HER-2, anti-CD20, and other bioactive and organic chemical agents.
  • a "therapeutically effective amount" of an active agent such as a PRO polypeptide or agonist or antagonist thereto or an anti-PRO antibody refers to an amount effective in the treatment of a cardiovascular, endothelial or angiogenic disorder in a mammal and can be determined empirically.
  • an "effective amount" of an active agent such as a PRO polypeptide or agonist or antagonist thereto or an anti-PRO antibody refers to an amount effective for carrying out a stated pu ⁇ ose, wherem such amounts may be determined empirically for the desired effect.
  • PRO polypeptide and "PRO” as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein.
  • PRO/numberpolypeptide and “PRO/number” wherein the term “number” is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein).
  • the PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods.
  • a “native sequence PRO polypeptide” comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means.
  • the term "native sequence PRO polypeptide” specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced fonns) and naturally-occurring allelic variants of the polypeptide.
  • the native sequence PRO polypeptides disclosed herein are mature or full-length native sequencepolypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.
  • the PRO polypeptide "extracellular domain” or “ECD” refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 1% of such transmembrane and or cytoplasmic domains and preferably, will have less than 0.5? of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of tlie domain as initially identified herein.
  • an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are comtemplated by the present invention.
  • the approximate location of the "signal peptides" of the various PRO polypeptides disclosed herein are shown in the present specification and/or the accompanying figures.
  • the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al, Prot. Eng.. 10:1-6 (1997) and von Heinje et al, Nucl Acids Res.,
  • PRO polypeptide variant means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signalpeptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein.
  • Such PRO polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence.
  • a PRO polypeptide variant will have at least about 80%, 81%, 82%, 83%, 84%,
  • PRO variant polypeptides are at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150 or 200 amino acids in length and alternatively at least about 300 amino acids hi length, or more.
  • Percent (%) amino acid sequence identity with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in a PRO sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for p poses of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • % amino acid sequence identity values used herein are obtained as described above using tlie ALIGN-2 sequence comparison computer program. However, % amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al, Nucleic Acids Res., 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from http ://www.ncbi.nlm.nih. go v. or otherwise obtained from the National Institute of Health, Bethesda, MD.
  • tlie % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acids residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (/. e. , the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest.
  • amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.
  • PRO variant polynucleotide or "PRO variant nucleic acid sequence” means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein.
  • a PRO variant polynucleotide will have at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,
  • nucleic acid sequence identity 93%, 94%, 95%, 96%, 97% or 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of full-length PRO polypeptide sequence as disclosed herein. Variants do not encompass tlie native nucleotide sequence.
  • PRO variant polynucleotides are at least about 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 450, or 600 nucleotides in length and alternatively at least about 900 nucleotides in length, or more.
  • Percent (%) nucleic acid sequence identity with respect to the PRO polypeptide-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in a PRO polypeptide-encoding nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for pmposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software.
  • the ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows:
  • % nucleic acid sequence identity values used herein are obtained as described above using the ALIGN-2 sequence comparison computer program. However, % nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al,
  • % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows:
  • % nucleic acid sequence identity values may also be generated using the WU-BLAST-
  • a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of tlie PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide- encoding nucleic acid molecule of interest.
  • nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.
  • PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encodmg the full-length PRO polypeptide as shown in the specification herein and accompanying figures.
  • PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.
  • isolated when used to describe the various polypeptides disclosed herein, means a polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Preferably, the isolated polypeptide is free of association with all components with which it is naturally associated. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
  • the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of tlie PRO natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
  • An "isolated" nucleic acid molecule encoding a PRO polypeptide or an “isolated” nucleic acid molecule encoding an anti-PRO antibody is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the PRO-encoding nucleic acid or the natural source of the anti-PRO-encoding nucleic acid.
  • the isolated nucleic acid is free of association with all components with which it is naturally associated.
  • An isolated PRO-encoding nucleic acid molecule or an isolated anti-PRO-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature.
  • Isolated nucleic acid molecules therefore are distinguished from the PRO-encoding nucleic acid molecule or from the anti-PRO-encoding nucleic acid molecule as it exists in natural cells.
  • an isolated nucleic acid molecule encoding a PRO polypeptide or an isolated nucleic acid molecule encoding an anti- PRO antibody includes PRO-nucleic acid molecules or anti-PRO-nucleic acid molecules contained in cells that ordinarily express PRO polypeptides or anti-PRO antibodies where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
  • control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism.
  • the control sequences that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
  • Eukaryotic cells are known to utilize, for example, promoters, polyadenylation signals, and enhancers.
  • Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
  • DNA for a presequence or secretory leader is operably linked to DNA for a PRO polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked” means that the DNA sequences being linked are contiguous, and, in the case ofa secretory leader, contiguous and in the same reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • “Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature that can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see, Ausubel et al, Current Protocols in Molecular Biology (Wiley Interscience Publishers, 1995).
  • Stringent conditions or “high-stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example, 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as forrnamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin 0.1% Ficoll/0.1% ⁇ olyvinyl ⁇ yrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ l), 0.1% SDS, and 10%
  • Moderately-stringent conditions may be identified as described by Sambrook et al, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Press, 1989), and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength, and % SDS) less stringent than those described above.
  • washing solution and hybridization conditions e.g., temperature, ionic strength, and % SDS
  • moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mMNaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ l denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C.
  • a solution comprising: 20% formamide, 5 x SSC (150 mMNaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ l denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C.
  • the skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate
  • epitope-tagged when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide".
  • the tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused.
  • the tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes.
  • Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).
  • Active or “activity” in the context of PRO variants refers to form(s) of PRO proteins that retain the biologic and/or immuno logic activities of a native or naturally-occurring PRO polypeptide.
  • Bioactivity in the context of a molecule that antagonizes a PRO polypeptide that can be identified by the screening assays disclosed herein (e.g. , an organic or inorganic small molecule, peptide, etc.) is used to refer to the ability of such molecules to bind or complex with the PRO polypeptide identified herein, or otherwise interfere with the interaction of the PRO polypeptide with other cellular proteins or otherwise inhibits the transcription or translation of the PRO polypeptide.
  • Particularly preferred biological activity includes cardiac hypertrophy, activity that acts on systemic disorders that affect vessels, such as diabetes mellitus, as well as diseases of the arteries, capillaries, veins, and or lymphatics, and cancer.
  • Antagonist is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes one or more of tlie biological activities of a native PRO polypeptide disclosed herein, for example, if applicable, its mitogenic or angiogenic activity.
  • Antagonists of a PRO polypeptide may act by interfering with the binding ofa PRO polypeptide to a cellular receptor, by incapacitating or killing cells that have been activated by a PRO polypeptide, or by interfering with vascular endothelial cell activation after binding ofa PRO polypeptide to a cellular receptor. All such points of intervention by a PRO polypeptide antagonist shall be considered equivalent for pmposes of this invention.
  • the antagonists inhibit the mitogenic, angiogenic, or other biological activity of PRO polypeptides, and thus are useful for the treatment of diseases or disorders characterized by undesirable excessive neovascularization, including by way of example tumors, and especially solid malignant tumors, rheumatoid arthritis, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, age- related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hype ⁇ lasias (including Grave's disease), corneal and other tissue transplantation, and chronic inflammation.
  • tumors and especially solid malignant tumors, rheumatoid arthritis, psoriasis, atherosclerosis, diabetic and other retinopathies, retrolental fibroplasia, age- related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hype ⁇ lasias (including Grave's disease), corneal and other tissue
  • the antagonists also are useful for the treatment of diseases or disorders characterized by undesirable excessive vascular permeability, such as edema associated with brain tumors, ascites associated with malignancies, Meigs' syndrome, lung inflammation, nephrotic syndrome, pericardial effusion (such as that associated with pericarditis), andpleural effusion.
  • vascular permeability such as edema associated with brain tumors, ascites associated with malignancies, Meigs' syndrome, lung inflammation, nephrotic syndrome, pericardial effusion (such as that associated with pericarditis), andpleural effusion.
  • the term "agonist” is used in tlie broadest sense and includes any molecule that mimics a biological activity ofa native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments, or amino acid sequence variants of native PRO polypeptides, peptides, small organic molecules, etc.
  • PRO polypeptide receptor refers to a cellular receptor for a PRO polypeptide, ordinarily a cell-surface receptor found on vascular endothelial cells, as well as variants thereof that retain the ability to bind a PRO polypeptide.
  • Antibodies are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules that lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.
  • antibody is used in the broadest sense and specifically covers, without limitation, intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments, so long as they exhibit the desired biological activity.
  • “Native antibodies” and “native immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among tlie heavy chains of different immunoglobulin isotypes. Eachheavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V H ) followed by a number of constant domains.
  • V H variable domain
  • Each light chain has a variable domain at one end (V L ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain.
  • Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains.
  • the term "variable” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody to and for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains.
  • CDRs complementarity-determining regions
  • variable domains The more highly conserved portions of variable domains are called the framework regions (FR).
  • the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a ⁇ -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the ⁇ -sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies. See, Kabat et al. NIH Publ No.91-3242. Vol. I, pages 647-669 (1991).
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of tlie antibody in antibody-dependent cellular toxicity.
  • Antibody fragments comprise a portion of an intact antibody, preferably the antigen-binding or variable region of the intact antibody.
  • antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments; diabodies; linear antibodies (Zapata et al , Protein Eng..8(10): 1057- 1062 ( 1995)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
  • Fv is the minimum antibody fragment that contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V H -V L dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • the Fab fragment also contains the constant domain of the light chain and the first constant domain (CHI) of the heavy chain.
  • Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free tfiiol group.
  • F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments that have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • the "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ( ) and lambda ( ⁇ ), based on the amino acid sequences of then constant domains.
  • immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM; and several of these may be further divided into subclasses (isotypes), e.g., IgGl , IgG2, IgG3, IgG4, IgA, and IgA2.
  • the heavy-chain constant domains that correspond to the different classes of immunoglobulins are called , ⁇ , e, ⁇ , and ⁇ , respectively.
  • the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i. e. , the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al, Nature.256: 495 (1975), ormay be made by recombinant DNA methods (see, e.g., U.S. PatentNo.4,816,567).
  • the “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et a , Nature, 352: 624-628 (1991) and Marks et al, J.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (hnmunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences hi antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
  • chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences hi antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab') 2) or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a CDR of the recipient are replaced by residues from a CDR ofa non-human species (donor antibody) such as mouse, rat or rabbit having the deshed specificity, affinity, and capacity.
  • donor antibody such as mouse, rat or rabbit having the deshed specificity, affinity, and capacity.
  • Fv FR residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those ofa human immunoglobulin sequence.
  • the humanized antibody preferably also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • the humanized antibody includes a PRIMATIZEDTM antibody wherein tlie antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.
  • "Single-chain Fv” or “sFv” antibody fragments comprise the V H and V L domains of an antibody, wherein these domains are present in a single polypeptide chain.
  • the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains that enables the sFv to form the desired structure for antigen binding.
  • a polypeptide linker between the V H and V L domains that enables the sFv to form the desired structure for antigen binding.
  • Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al, Proc. Natl Acad. Sci. USA. 90: 6444-6448 (1993).
  • an "isolated” antibody is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • tlie antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
  • Isolated antibody includes the antibody in situ within recombmant cells, since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • An antibody that "specifically binds to" or is “specific for” a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide witliout substantially binding to any other polypeptide or polypeptide epitope.
  • label when used herein refers to a detectable compound or other composition that is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody.
  • the label may be detectable by itself (e.g. , radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition that is detectable.
  • Radionuclides that can serve as detectable labels include, for example, 1-131, 1-123, 1-125, Y-90, Re-188, At-211, Cu-67, Bi-212, and Pd-109.
  • the label may also be a non- detectable entity such as a toxin.
  • solid phase is meant a non-aqueous matrix to which an antibody of the present invention can adhere.
  • solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
  • the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.
  • a “liposome” is a small vesicle composed of various types of lipids, phospholipids and/or surfactant that is useful for delivery of a drug (such as the PRO polypeptide or antibodies thereto disclosed herein) to a mammal
  • the components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
  • immunoadliesin designates antibody-like molecules that combine tlie binding specificity of aheterologous protein (an “ adhesin”) with the effector functions of immunoglobulin constant domains.
  • the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity that is other than the antigen recognition and binding site of an antibody (i.e., is “heterologous"), and an immunoglobulin constant domain sequence.
  • the adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site ofa receptor or a ligand.
  • the immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG- 1 , IgG- 2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD, or IgM.
  • immunoglobulin such as IgG- 1 , IgG- 2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD, or IgM.
  • Table 1 provides the complete source code for the ALIGN-2 sequence comparison computer program. This source code may be routinely compiled for use on a UNIX operating system to provide the ALIGN-2 sequence comparison computer program.
  • Tables 2-5 show hypothetical exemplifications for using the below described method to determine % amino acid sequence identity (Tables 2-3) and % nucleic acid sequence identity (Tables 4-5) using tlie ALIGN-2 sequence comparison computer program, wherein "PRO” represents the amino acid sequence of a hypothetical PRO polypeptide of interest, “Comparison Protein” represents the amino acid sequence of a polypeptide against which the "PRO” polypeptide of interest is being compared, "PRO-DNA” represents a hypothetical PRO-encoding nucleic acid sequence of interest, “Comparison DNA” represents the nucleotide sequence of a nucleic acid molecule against which tlie “PRO-DNA” nucleic acid molecule of interest is being compared, “X”, “Y”, and “Z” each represent different hypothetical amino acid residues and "N", “L” and “V” each represent different hypothetical nucleotides.
  • filel and f ⁇ le2 are two dna or two protein sequences.
  • Max file length is 65535 (limited by unsigned short x in the jmp struct)
  • a sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
  • the program may create a tmp file in /tmp to hold info about traceback.
  • (ndelx > MAXJMP && xx > dx[id].jp.x[ij] +MX)
  • stripname( ) strip any path and prefix from a seqname */
  • static nm matches in core — for checking */ static lmax; /* lengths of stripped file names */ static ij[2]; /* jmp index for a path */ static nc[2]; /* number at start of current line */ static niP]; /* current elem number — for gapping */ static siz[2]; static char *ps[2]; /* ptr to current element */ static char *po[2]; /* ptr to next output char slot */ static char oouutt[[22]][[IP_LINE] ; /* output line */ static char starfP ] ⁇ ]; /* set by stars( ) */
  • *ps[i] toupper(*ps[i]); po[i] + + ; ps[i] + + ;
  • *py++ *px; else if (islower(*px))
  • *py+ + toupper(*px); if (index("ATGCU",*(py-l))) natgc+ + ; ⁇ ⁇
  • ⁇ int fd -1; int siz, iO, il; register i, j, xx; if ( ⁇ ⁇
  • % amino acid sequence identity (the number of identically matching amino acid residues between the two polypeptide sequences as determined by
  • PRO variants can be prepared.
  • PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide.
  • amino acid changes may alter post-translational processes of the PRO polypeptide such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.
  • Variations in tlie native full-length sequence PRO polypeptide or in various domains of the PRO polypeptide described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934.
  • Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO polypeptide that results in a change in the amino acid sequence of the PRO polypeptide as compared with the native sequence PRO polypetide.
  • the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO polypeptide.
  • Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO polypeptide with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology.
  • Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement ofa leucine with a serine, i. e. , conservative amino acid replacements.
  • Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
  • conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and tlie products screened.
  • Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • Naturally occurring residues are divided into groups based on common side-chain properties:
  • hydrophobic norleucine, met, ala, val, leu, ile
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
  • the variations can be made using methods known in the art such as oligonucleotide-mediated (site- directed) mutagenesis, alanine scanning, and PCR mutagenesis.
  • Site-directed mutagenesis [Carter et al, Nucl. Acids Res.. 13:4331 (1986); Zoller et al, Nucl. Acids Res.. .10:6487 (1987)]
  • cassette mutagenesis [Wells et al, Gene, 34:315 (1985)]
  • restriction selection mutagenesis [Wells etal, Philos. Trans. R. Soc. London SerA.317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA.
  • Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence.
  • preferred scanning amino acids are relatively small, neutral amino acids.
  • amino acids include alanine, glycine, serine, and cysteine.
  • Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)].
  • Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol.. 150: 1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.
  • Covalent modifications of PRO polypeptides are included within the scope of this invention.
  • One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PRO polypeptide.
  • Derivatization with bifunctional agents is useful, for instance, for crosshnking the PRO polypeptide to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice- versa.
  • crosslinking agents include, e.g., 1,1 -bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N- hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-difhiobis(succinimidylpropionate), bifunctional maleimides such as bis-N- maleimido-l,8-octane and agents such as metl ⁇ yl-3-[(p-azidophenyl)dithio]pro ⁇ ioimidate.
  • 1,1 -bis(diazoacetyl)-2-phenylethane glutaraldehyde
  • N- hydroxysuccinimide esters for example, esters with 4-azidosalicylic acid
  • homobifunctional imidoesters including disuccinimidyl esters such as 3,
  • Another type of covalent modification of the PRO polypeptide included within tlie scope of this invention comprises altering the native glycosylation pattern of the polypeptide.
  • "Altering the native glycosylation pattern” is intended for purposes herein to mean deleting one or more carbohydrate moieties found in the native sequence PRO polypeptide (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO polypeptide.
  • the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.
  • Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence.
  • the alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO polypeptide (for O-linked glycosylation sites).
  • the PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.
  • Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Grit, Rev. Biochem.. pp.259-306 (1981). Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al, Arch. Biochem.
  • Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use ofa variety of endo- and exo-glycosidases as described by Thotakura et al, Meth. Enzvmol.. 138:350 (1987).
  • Another type of covalent modification of the PRO polypeptide comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
  • the PRO polypeptide of the present invention may also be modified in a way to form a chimeric molecule comprising the PRO polypeptide fused to another, heterologous polypeptide or amino acid sequence.
  • such a chimeric molecule comprises a fusion of the PRO polypeptide with a protein transduction domain which targets the PRO polypeptide for delivery to various tissues and more particularly across the brain blood barrier, using, for example, the protein transduction domain of human immunodeficiency virus TAT protein (Schwarze et al, 1999, Science 285: 1569-72).
  • such a chimeric molecule comprises a fusion of the PRO polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind.
  • the epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO polypeptide. The presence of such epitope-tagged forms of the PRO polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag.
  • tag polypeptides and their respective antibodies are well known in the art.
  • Examples include pbly-histidine (poly-His) or poly-histidine-glycine (poly- His-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al, Mol. Cell. Biol.. 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al, Molecular and Cellular Biology. 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody
  • tag polypeptides include the Flag-peptide [Hopp e/fl/.,BioTechnologv, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martinet al. Science.255:192-194 (1992)1; an ⁇ -tubulin epitope peptide [Skinner etal, J. Biol. Chem..266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyerniutli et al, Proc. Natl. Acad. Sci.
  • the chimeric molecule may comprise a fusion of tlie PRO polypeptide with an immunoglobulin or a particular region of an immunoglobulin.
  • a bivalent form of the chimeric molecule also referred to as an "immunoadhesin”
  • Ig fusions preferably include tlie substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule.
  • the immunoglobulin fusion includes the hinge, CH2 and CH3 , or the hinge, CH 1 , CH2 and CH3 regions of an IgG 1 molecule.
  • the immunoglobulin fusion includes the hinge, CH2 and CH3 , or the hinge, CH 1 , CH2 and CH3 regions of an IgG 1 molecule.
  • the present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides.
  • cDNAs encoding PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted that proteins produced in separate expression rounds may be given different PRO numbers but tlie UNQ number is unique for any given DNA and the encoded protein, and will not be changed. However, for sake of simplicity, in the present specification the protein encoded by tlie PRO DNA as well as all further native homologues and variants included in the foregoing definition of PRO polypeptides, will be referred to as "PRO" regardless of their origin or mode ofpreparation.
  • PRO polypeptide sequence may be produced by direct peptide synthesis using solid-phase techniques. See, e.g. , Stewart et al, Solid-Phase Peptide Synthesis (W.H. Freeman Co. : San Francisco, CA, 1969); Merrifield, J. Am. Chem. Soc. 85: 2149-2154 (1963). In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, with an Applied Biosystems
  • PRO polypeptide Synthesizer Frazier City, CA
  • Various portions of the PRO polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full- length PRO polypeptide.
  • DNA encoding the PRO polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the mRNA encoding the PRO polypeptide and to express it at a detectable level. Accordingly, DNAs encoding the human PRO polypeptide can be conveniently obtained from cDNA libraries prepared from human tissues, such as described in the Examples. The gene encoding tlie PRO polypeptide may also be obtained from a genomic library or by oligonucleotide synthesis. Libraries can be screened with probes (such as antibodies to the PRO polypeptide or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it.
  • probes such as antibodies to the PRO polypeptide or oligonucleotides of at least about 20-80 bases
  • Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al, supra.
  • An alternative means to isolate the gene encoding the PRO polypeptide is to use PCR methodology. Sambrook et al, supra; Dieffenbach et al, PCR Primer: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1995).
  • the oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized.
  • the oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include tlie use of radiolabels like 32 P-labeled ATP, biotinylation, or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al, supra.
  • Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined through sequence alignment using computer software programs such as
  • Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al, supra, to detect precursors and processing intermediates of mRNA that may not have been reverse- transcribed into cDNA.
  • Host cells are transfected or transformed with expression or cloning vectors described herein for PRO polypeptide production and cultured hi conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the deshed sequences.
  • the culture conditions such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: A Practical Approach. M. Butler, ed. (IRL Press, 1991) and Sambrook et al, supra.
  • transfection Methods of transfection are known to the ordinarily skilled artisan, for example, CaP0 4 treatment and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells.
  • the calcium treatment employing calcium chloride, as described in Sambrook et al, supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell- wall barriers.
  • Infection with Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw et al. , Gene. 23: 315 (1983) and WO 89/05859 published 29 June 1989.
  • DNA into cells such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene or polyornifhine, may also be used.
  • polycations e.g., polybrene or polyornifhine
  • transforming mammalian cells see, eown et al, Methods in Enzymology. 185: 527-537 (1 90) and Mansour et al, Nature. 336: 348-352 (1988).
  • Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells.
  • Suitable prokaryotes include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli.
  • Various E. coli strains are publicly available, such as E. co/JK12 strain MM294 (ATCC 31,446); E. co/iX1776 (ATCC 31,537); £ coli strain W3110 (ATCC 27,325); and K5 772 (ATCC 53,635).
  • suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B. subtilis and B. licheniformis (e.g.,B. licheniformis 41P disclosed in DD 266,710 published 12 April 1989), Pseudomonas such as
  • Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes.
  • strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1 A2, which has the complete genotype tonA ; E. coli W3110 strain 9E4, which has the complete genotype tonA ptr3; E.
  • coli W3110 strain 27C7 (ATCC 55,244), which has tlie complete genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompTkan r ;
  • E. coli WS 110 strain 37D6 which has the complete genotype tonAptr3phoA E15 (argF-lac) 169 degP ompT rbs7ilvGkan r ;E. coliW3U0 stram40B4, which is strain 37D6 with a non-kanarnycin resistant degP deletion mutation; and an E. coli strain having mutant periplasmic protease disclosed in U.S. Patent No.4,946,783 issued 7 August 1990.
  • in vitro methods of cloning e.g., PCR or other nucleic acid polymerase reactions, are suitable.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding tlie PRO polypeptide.
  • Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism.
  • Others include Schizosaccharomyce pombe (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); Kluyveromyces hosts O ⁇ .S. Patent No. 4,943,529; Fleer et al,
  • K. lactis MW98-8C, CBS683, CBS4574; Louvencourt et al, J. Bacteriol. 737 [1983]
  • K. fragilis ATCC 12,424)
  • K. bulgaricus ATCC 16,045)
  • K. wickeramii ATCC 24,178
  • ⁇ waltii ATCC 56,500
  • Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of H ⁇ nsenul ⁇ , Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula.
  • yeast capable of growth on methanol selected from the genera consisting of H ⁇ nsenul ⁇ , Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula.
  • a list of specific species that are exemplary of this class of yeasts maybe found in C. Anthony, The Biochemistry of Methylotrophs. 269 (1982).
  • Suitable host cells for the expression of nucleic acid encoding glycosylated PRO polypeptides are derived from multicellular organisms.
  • invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells.
  • useful mammalian host cell lines include Chinese hamster ovary
  • CHO monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth hi suspension culture, Graham et a/.. J. Gen. Virol..36: 59 (1977)); Chinese hamster ovary cellsADHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA. 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod.. 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor
  • the nucleic acid e.g., cDNA or genomic DNA
  • a replicable vector for cloning (amplification of the DNA) or for expression.
  • Various vectors are publicly available.
  • the vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage.
  • the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
  • Vector components generally include, but are not limited to, one or more of a signal sequence if the sequence is to be secreted, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence.
  • the PRO polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • a heterologous polypeptide which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide.
  • the signal sequence may be a component of the vector, or it may be a part of the DNA encoding the PRO polypeptide that is inserted into the vector.
  • the signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders.
  • the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces ⁇ -factor leaders, the latter describedi U.S. PatentNo.5,010,182), or acid phosphatase leader, the C ⁇ / ⁇ z ' c ⁇ ms glucoamylase leader (EP 362, 179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990.
  • alpha factor leader including Saccharomyces and Kluyveromyces ⁇ -factor leaders, the latter describedi U.S. PatentNo.5,010,182
  • acid phosphatase leader the C ⁇ / ⁇ z ' c ⁇ ms glucoamylase leader
  • mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
  • Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses.
  • the origin of replication from the plasmid ⁇ BR322 is suitable for most Gram-negative bacteria, the 2 ⁇ plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovims, VSV, or BPV) are useful for cloning vectors in mammalian cells.
  • Selection genes will typically contain a selection gene, also termed a selectable marker.
  • Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding the PRO polypeptide such as DHFR or thymidine kinase.
  • An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al, Proc. Natl. Acad. Sci. USA, 77: 4216 (1980).
  • a suitable selection gene for use in yeast is the trpl gene present in the yeastplasmidYRp7. Stinchcomb et al.. Nature.282: 39 (1979); Kingsman et al. , Gene, 7: 141 (1979); Tschemper etal.
  • the trpl gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85: 12 (1977).
  • Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding the PRO polypeptide to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the ⁇ -lactamase and lactose promoter systems (Chang et al, Nature.
  • suitable promoting sequences for use with yeast hosts include the promoters for 3- phosphoglycerate kinase (Hitzeman et al, J. Biol. Chem..255: 2073 (1980)) or other glycolytic enzymes (Hess et al. J. Adv. Enzyme Reg..7: 149 (1968); Holland, Biochemistry. 17: 4900 (1978)), such as enolase, glyceraldehyde-
  • yeast promoters that are inducible promoters having the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3 -phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
  • PRO nucleic acid transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published
  • adenovims such as Adenovirus 2
  • bovine papilloma virus such as Adenovirus 2
  • bovine papilloma virus such as avian sarcoma virus
  • cytomegalovirus such as aretrovirus
  • hepatitis-B virus such as Simian Virus 40 (SV40)
  • heterologous mammalian promoters e.g., the actin promoter or an immunoglobulin promoter
  • heat-shock promoters provided such promoters are compatible with the host cell systems.
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription.
  • Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, ⁇ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus.
  • Examples include the SV40 enhancer on the late side of tlie replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • the enhancer may be spliced into the vector at a position 5' or 3 ' to the sequence coding for PRO polypeptides, but is preferably located at a site 5' from the promoter.
  • Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or vhal DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments hi the untranslated portion of tlie mRNA encoding the PRO polypeptide.
  • Gene amplification and/or expression may be measured in a sample dhectly, for example, by conventional
  • Southern blotting Northern blotting to quantitate the transcription of mRNA (Thomas, Proc. Natl. Acad. Sci. USA. 77:5201-5205 (1980)), dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein.
  • antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
  • Gene expression may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate dhectly the expression of gene product.
  • Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native-sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to DNA encoding the PRO polypeptide and encoding a specific antibody epitope.
  • PRO polypeptides may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., TRITON-XTM 100) or by enzymatic cleavage. Cells employed in expression of nucleic acid encoding the PRO polypeptide can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell-lysing agents. It may be deshed to purify tlie PRO polypeptide from recombinant cell proteins or polypeptides.
  • a suitable detergent solution e.g., TRITON-XTM 100
  • Cells employed in expression of nucleic acid encoding the PRO polypeptide can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell-lysing agents. It may be deshed to purify tlie PRO polypeptide from recombinant cell proteins or polypeptides.
  • the following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO polypeptide.
  • Various methods of protein purification may be employed and such methods are known in the art and described, for example, in Deutscher, Methods in
  • assays can be used to test the polypeptide herein for cardiovascular, endothelial, and angiogenic activity.
  • Such assays include those provided in the Examples below.
  • Assays for testing for endothelin antagonist activity include a rat heart ventricle binding assay where the polypeptide is tested for its ability to inhibit iodinized endothelin- 1 binding in a receptor assay, an endothelin receptor binding assay testing for intact cell binding of radiolabeled endothelin- 1 using rabbit renal artery vascular smooth muscle cells, an inositol phosphate accumulation assay where functional activity is determined in Rat-1 cells by measuring intra-cellular levels of second messengers, an arachidonic acid release assay that measures the ability of added compounds to reduce endothelin-stimulated arachidonic acid release in cultured vascular smooth muscles, in vitro (isolated vessel) studies using endothelium from male New Zealand rabbits, and in vivo studies using male Sprague-Dawley rats.
  • Assays for tissue generation activity include, without limitation, those described in WO 95/16035 (bone, cartilage, tendon); WO 95/05846 (nerve, neuronal), and WO 91/07491 (skin, endothelium).
  • Assays for wound-healing activity include, for example, those described in Winter, Epidermal Wound Healing, Maibach, HI and Rovee, DT, eds. (Year Book Medical Publishers, Inc., Chicago), pp.71- 112, as modified by the article of Eaglstein and Mertz, J. Invest. Dermatol.. 71: 382-384 (1978).
  • An assay to screen for a test molecule relating to a PRO polypeptide that binds an endothelin Bj (ETB,) receptor polypeptide and modulates signal transduction activity involves providing a host cell transformed with a DNA encoding endothelin B, receptor polypeptide, exposing the cells to the test candidate, and measuring endothelin B : receptor signal transduction activity, as described, e.g., in U.S. Pat. No. 5,773,223.
  • endothelin B : receptor signal transduction activity as described, e.g., in U.S. Pat. No. 5,773,223.
  • cardiac hypertrophy assays include induction of spreading of adult rat cardiac myocytes.
  • ventricular myocytes are isolated from a single (male Sprague-Dawley) rat, essentially following a modification of the procedure described in detail by Piper et al. , "Adult ventricular rat heart muscle cells” in Cell Culture Techniques in Heart and Vessel Research. H.M. Piper, ed. (Berlin: Springer- Verlag, 1990), pp. 36-60.
  • This procedure permits the isolation of adult ventricular myocytes and the long-term culture of these cells in the rod-shaped phenotype.
  • Phenylephrine and Prostaglandin F 2ct (PGF 2 ⁇ ) have been shown to induce a spreading response in these adult cells.
  • PGF 2 ⁇ Prostaglandin F 2ct
  • an in vivo assay is a test for inhibiting cardiac hypertrophy induced by fluprostenol in vivo.
  • This pharmacological model tests tlie ability of the PRO polypeptide to inhibit cardiac hypertrophy induced in rats (e.g., male Wistar or Sprague-Dawley) by subcutaneous injection of fluprostenol (an agonist analog of PGF 2lI ). It is known that rats with pathologic cardiac hypertrophy induced by myocardial infarction have chronically elevated levels of extractable PGF 2o in their myocardium. Lai et al, Am. J. Physiol. (Heart Che. Physiol.). 271: H2197- H2208 (1996).
  • factors that can inhibit the effects of fluprostenol on myocardial growth in vivo are potentially useful for treating cardiac hypertrophy.
  • the effects of the PRO polypeptide on cardiac hypertrophy are determined by measuring the weight of heart, ventricles, and left ventricle (normalized by body weight) relative to fluprostenol-treated rats not receiving the PRO polypeptide.
  • an in vivo assay is the pressure-overload cardiac hypertrophy assay.
  • in vivo testing it is common to induce pressure-overload cardiac hypertrophy by constriction of the abdominal aorta of test animals.
  • rats e.g., male Wistar or Sprague-Dawley
  • the abdominal aorta of each rat is narrowed down just below the diaphragm.
  • the aorta is exposed through a surgical incision, and a blunted needle is placed next to the vessel.
  • the aorta is constricted with a ligature of silk thread around the needle, which is immediately removed and which reduces the lumen of the aorta to the diameter of the needle.
  • This approach is described, for example, in Rossi et al, Am. Heart J.. 124: 700-709 (1992) and O'Rourke and Reibel, P.S.E.M.B.. 200: 95-100 (1992).
  • MI myocardial infarction
  • Animal models of tumors and cancers include both non-recombinant and recombinant (transgenic) animals.
  • Non-recombinant animal models include, for example, rodent, e.g., murine models.
  • Such models can be generated by introducing tumor cells into syngeneic mice using standard techniques, e.g., subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under tlie renal capsule, or orthopin implantation, e.g., colon cancer cells implanted in colonic tissue.
  • standard techniques e.g., subcutaneous injection, tail vein injection, spleen implantation, intraperitoneal implantation, implantation under tlie renal capsule, or orthopin implantation, e.g., colon cancer cells implanted in colonic tissue.
  • the autosomal recessive nu gene has been introduced into a very large number of distinct congenic strains of nude mouse, including, for example, ASW, A/He, AKR, BALB/c, B10.LP, C17, C3H, C57BL, C57, CBA, DBA, DDD, list, NC, NFR, NFS, NFS N, NZB, NZC, NZW, P, Rffl, and S JL.
  • a wide variety of other animals with inherited immunological defects other than the nude mouse have been bred and used as recipients of tumor xenografts. For further details see, e.g., The Nude Mouse in Oncology Research. E. Boven and B. Winograd, eds. (CRC Press, Inc., 1991).
  • the cells introduced into such animals can be derived from known tumor/cancer cell lines, such as any of tlie above-listed tumor cell lines, and, for example, the B 104- 1-1 cell line (stable NIH-3T3 cell line transfected with the neu protooncogene); ras-transfected NIH-3T3 cells; Caco-2 (ATCC HTB-37); or a moderately well- differentiated grade II human colon adenocarcinoma cell line, HT-29 (ATCC HTB-38); or from tumors and cancers. Samples of tumor or cancer cells can be obtained from patients undergoing surgery, using standard conditions involving freezing and storing in liquid nitrogen. Karmali et al, Br. J. Cancer, 48: 689-696 (1983).
  • Tumor cells can be introduced into animals such as nude mice by a variety of procedures.
  • the subcutaneous (s.c.) space in mice is very suitable for tumor implantation.
  • Tumors can be transplanted s.c. as solid blocks, as needle biopsies by use ofa trochar, or as cell suspensions.
  • tumor tissue fragments of suitable size are introduced into the s.c. space.
  • Cell suspensions are freshly prepared from primary tumors or stable tumor cell lines, and injected subcutaneously.
  • Tumor cells can also be injected as subdermal implants. In this location, the inoculum is deposited between tlie lower part of the dermal connective tissue and the s.c. tissue.
  • Animal models of breast cancer can be generated, for example, by implanting rat neuroblastoma cells (from which the neu oncogene was initially isolated), or new-transformed NIH-3T3 cells into nude mice, essentially as described by Drebin et al. Proc. Nat. Acad. Sci. USA, 83: 9129-9133 (1986).
  • animal models of colon cancer can be generated by passaging colon cancer cells in animals, e.g. , nude mice, leading to the appearance of tumors in these animals.
  • An orthotopic transplant model of human colon cancer in nude mice has been described, for example, by Wang et al, Cancer Research, 54: 4726-4728 (1994) and Too et al, Cancer Research. 55: 681-684 (1995). This model is based on the so-called “METAMOUSETM” sold by AntiCancer, Inc., (San Diego, California).
  • Tumors that arise in animals canbe removed and cultured in vitro. Cells from tlie in vitro cultures can then be passaged to animals. Such tumors can serve as targets for further testing or drug screening. Alternatively, the tumors resulting from the passage can be isolated and RNA from pre-passage cells and cells isolated after one or more rounds of passage analyzed for differential expression of genes of interest. Such passaging techniques can be performed with any known tumor or cancer cell lines.
  • Meth A, CMS4, CMS5, CMS21, and WEHI-164 are chemically induced fibrosarcomas of BALB/c female mice (DeLeo et al, J. Exp. Med., 146: 720 (1977)), which provide a highly controllable model system for studying the anti-tumor activities of various agents.
  • tumor cells are propagated in vitro in cell culture. Prior to injection into the animals, the cell lines are washed and suspended in buffer, at a cell density of about lOxlO 6 to 10xl0 7 cells/ml.
  • mice are then infected subcutaneously with 10 to 100 ⁇ l of the cell suspension, allowing one to three weeks for a tumor to appear.
  • the Lewis lung (3LL) carcinoma of mice which is one of the most thoroughly studied experimental tumors, can be used as an investigational tumor model. Efficacy in this tumor model has been correlated with beneficial effects in the treatment of human patients diagnosed with small-cell carcinoma of the lung
  • SCCL Single cell lung cancer
  • This tumor can be introduced in normal mice upon injection of tumor fragments from an affected mouse or of cells maintained h culture. Zupi et al, Br. J. Cancer.41: suppl.4, 30 (1980). Evidence indicates that tumors can be started from injection of even a single cell and that a very high proportion of infected tumor cells survive. For further information about this tumor model see, Zacharski, Haemostasis. 16: 300-320 (1986).
  • One way of evaluating the efficacy ofa test compound in an animal model with an implanted tumor is to measure tlie size of the tumor before and after treatment. Traditionally, the size of implanted tumors has been measured with a slide caliper in two or three dimensions.
  • the measure limited to two dimensions does not accurately reflect the size of the tumor; therefore, it is usually converted into the corresponding volume by using a mathematical formula. However, the measurement of tumor size is very inaccurate.
  • the therapeutic effects of a drug candidate can be better described as treatment-induced growth delay and specific growth delay.
  • necrosis and inflammatory responses following treatment may actually result hi an increase in tumor size, at least initially. Therefore, these changes need to be carefully monitored, by a combination of a morphometric method and flow cytometric analysis.
  • recombinant (transgenic) animal models can be engineered by introducing the coding portion of the PRO gene identified herein into the genome of animals of interest, using standard techniques for producing transgenic animals.
  • Animals that can serve as a target for transgenic manipulation include, without limitation, mice, rats, rabbits, guinea pigs, sheep, goats, pigs, and non-human primates, e.g., baboons, chimpanzees and monkeys.
  • Techniques known in the art to introduce a transgene into such animals include pronucleic microinjection (U.S. Patent No. 4,873,191); retrovirus-mediated gene transfer into germ lines (e.g., Van der Putten et al, Proc. Natl. Acad.
  • transgenic animals include those that carry the transgene only in part of their cells ("mosaic animals").
  • the transgene can be integrated either as a single transgene, or in concatamers, e.g. , head-to-head or head-to-tail tandems. Selective introduction of a transgene into a particular cell type is also possible by following, for example, the technique of Lasko et al, Proc. Natl. Acad. Sci. USA.89: 6232- 636 (1992).
  • the expression of the transgene in transgenic animals can be monitored by standard techniques. For example, Southern blot analysis or PCR amplification can be used to verify the integration of the transgene.
  • the level of mRNA expression can then be analyzed using techniques such as in situ hybridization, Northern blot analysis, PCR, or irnmunocytochemistry.
  • the animals are furtlier examined for signs of tumor or cancer development.
  • "knock-out" animals can be constructed that have a defective or altered gene encoding a PRO polypeptide identified herein, as a result of homologous recombination between the endogenous gene encoding the PRO polypeptide and altered genomic DNA encoding the same polypeptide introduced hito an embryonic cell of the animal.
  • cDNA encoding a particular PRO polypeptide can be used to clone genomic DNA encoding that polypeptide in accordance with established techniques.
  • a portion of the genomic DNA encoding a particular PRO polypeptide can be deleted or replaced with another gene, such as a gene encoding a selectable marker that can be used to monitor integration.
  • flanking DNA typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector. See, e.g. , Thomas and Capecchi, Cell.51: 503 (1987) for a description of homologous recombination vectors.
  • the vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected. See, e.g., Li et al, Cell, 69: 915 (1992).
  • the selected cells are then injected into a blastocyst of an animal (e.g. , a mouse or rat) to form aggregation chimeras.
  • a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock-out" animal.
  • Progeny harbor ig the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA.
  • Knockout animals can be characterized, for instance, by then ability to defend against certain pathological conditions and by their development of pathological conditions due to absence of the PRO polypeptide.
  • SCC feline oral squamous cell carcinoma
  • Feline oral SCC is a highly invasive, malignant tumor that is the most common oral malignancy of cats, accounting for over 60% of the oral tumors reported in this species. It rarely metastasizes to distant sites, although this low incidence of metastasis may merely be a reflection of the short survival times for cats with this tumor.
  • These tumors are usually not amenable to surgery, primarily because of the anatomy of the feline oral cavity. At present, there is no effective treatment for this tumor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des compositions et procédés stimulant ou inhibant l'angiogenèse et la cardiovascularisation chez les mammifères dont l'homme. Il s'agit de compositions pharmaceutiques à base de polypeptides ou de leurs antagonistes identifiés comme convenant pour l'une ou plusieurs de ces utilisations. Les troubles susceptibles d'être diagnostiqués, prévenus ou traités par lesdites compositions comportent des traumatismes tels que des blessures, divers cancers, et des atteintes aux vaisseaux dont l'athérosclérose et l'hypertrophie cardiaque. L'invention porte également sur de nouveaux polypeptides et sur des molécules d'acides nucléiques codant pour eux. L'invention porte en outre sur des vecteurs et cellules hôtes comportant lesdites séquences d'acides nucléiques, sur des molécules de polypeptide chimères comprenant les polypeptides de l'invention fusionnés avec des séquences de polypeptides hétérologues, et des anticorps se fixant aux polypeptides de l'invention. L'invention porte par ailleurs sur les procédés d'obtention des polypeptides de l'invention.
EP01957073A 2000-06-23 2001-06-20 Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese Withdrawn EP1309620A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK08019420.2T DK2042597T3 (da) 2000-06-23 2001-06-20 Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
EP10182597A EP2275549A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
EP09004418A EP2075253A1 (fr) 2000-06-23 2001-06-20 Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
EP08019420.2A EP2042597B1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
EP09004417A EP2077276A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
EP09004415A EP2168980A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
EP14166919.2A EP2792747A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse

Applications Claiming Priority (72)

Application Number Priority Date Filing Date Title
US866028 1977-12-30
US664610 1996-06-18
US854280 1997-05-09
1999-03-19
US21363700P 2000-06-23 2000-06-23
US213637P 2000-06-23
US21955600P 2000-07-20 2000-07-20
US219556P 2000-07-20
US22062400P 2000-07-25 2000-07-25
US22066400P 2000-07-25 2000-07-25
US220664P 2000-07-25
US220624P 2000-07-25
WOPCT/US00/20710 2000-07-28
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
US22269500P 2000-08-02 2000-08-02
US222695P 2000-08-02
US643657 2000-08-17
US09/643,657 US6642024B1 (en) 1998-01-29 2000-08-17 Guanylate-binding protein
WOPCT/US00/23522 2000-08-23
PCT/US2000/023522 WO2001016319A2 (fr) 1999-08-31 2000-08-23 Compositions et procedes pour le traitement de maladies d'ordre immunologique
WOPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US23097800P 2000-09-07 2000-09-07
US230978P 2000-09-07
US66461000A 2000-09-18 2000-09-18
US66535000A 2000-09-18 2000-09-18
US665350 2000-09-18
US24292200P 2000-10-24 2000-10-24
US242922P 2000-10-24
US70923800A 2000-11-08 2000-11-08
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
WOPCT/US00/30952 2000-11-08
US709238 2000-11-08
PCT/US2000/030873 WO2001040465A2 (fr) 1999-11-30 2000-11-10 Compositions et procedes de traitement de maladies d'ordre immunologique
WOPCT/US00/30873 2000-11-10
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
WOPCT/US00/32678 2000-12-01
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
WOPCT/US00/34956 2000-12-20
US09/747,259 US6569645B2 (en) 1999-05-14 2000-12-20 IL-17 homologous polypeptides and therapeutic uses thereof
US747259 2000-12-20
US09/767,609 US20020042367A1 (en) 1997-11-25 2001-01-22 Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US767609 2001-01-22
US79649801A 2001-02-28 2001-02-28
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US796498 2001-02-28
WOPCT/US01/06520 2001-02-28
WOPCT/US01/06666 2001-03-01
PCT/US2001/006666 WO2001066740A2 (fr) 2000-03-03 2001-03-01 Compositions et methodes de traitement de maladies d'origine immune
US80270601A 2001-03-09 2001-03-09
US802706 2001-03-09
US80868901A 2001-03-14 2001-03-14
US808689 2001-03-14
US09/816,744 US6579520B2 (en) 1998-05-15 2001-03-22 IL-17 related mammalian cytokine polypeptides (IL-17E)
US816744 2001-03-22
US09/828,366 US20020010137A1 (en) 1997-09-18 2001-04-05 Methods and compositions for inhibiting neoplastic cell growth
US828366 2001-04-08
US854208 2001-05-10
US09/854,280 US7115398B2 (en) 1998-05-15 2001-05-10 IL-17 homologous polypeptides and therapeutic uses thereof
US09/854,208 US7217412B2 (en) 1998-05-15 2001-05-10 IL-17C related mammalian cytokine polypeptides
US09/866,034 US20030170864A1 (en) 2000-05-30 2001-05-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US866034 2001-05-25
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
PCT/US2001/017092 WO2001092331A2 (fr) 2000-05-30 2001-05-25 Compositions et methodes de traitement de maladies d'origine immune
WOPCT/US01/17092 2001-05-25
WOPCT/US01/17443 2001-05-30
US09/870,574 US6551799B2 (en) 1999-12-07 2001-05-30 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PCT/US2001/017443 WO2002016611A2 (fr) 2000-08-24 2001-05-30 Polypeptides d'interleukine-22, acides nucleiques codant pour lesdits polypeptides et methode permettant de traiter les affections pancreatiques
US870574 2001-05-30
WOPCT/US01/17800 2001-06-01
PCT/US2001/017800 WO2001093983A1 (fr) 2000-06-02 2001-06-01 Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides
PCT/US2001/019692 WO2002000690A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese

Related Child Applications (4)

Application Number Title Priority Date Filing Date
EP14166919.2A Division EP2792747A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
EP09004418A Division EP2075253A1 (fr) 2000-06-23 2001-06-20 Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
EP09004417A Division EP2077276A1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
EP08019420.2A Division EP2042597B1 (fr) 2000-06-23 2001-06-20 Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse

Publications (1)

Publication Number Publication Date
EP1309620A2 true EP1309620A2 (fr) 2003-05-14

Family

ID=56290154

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01957073A Withdrawn EP1309620A2 (fr) 2000-06-23 2001-06-20 Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese

Country Status (5)

Country Link
EP (1) EP1309620A2 (fr)
JP (1) JP2004506413A (fr)
AU (1) AU2001278852A1 (fr)
CA (1) CA2412211A1 (fr)
WO (1) WO2002000690A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871705A4 (fr) * 1995-06-05 2000-01-26 Human Genome Sciences Inc Facteur de croissance humain du type ccn
WO2002008284A2 (fr) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
ATE360032T1 (de) 1997-09-12 2007-05-15 Biogen Idec Inc Cystein-reiche rezeptoren-train
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
EP2333069A3 (fr) 1998-05-15 2011-09-14 Genentech, Inc. Utilisations therapeutiques de polypeptides homologues de il-17
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119113A1 (en) 1999-07-20 2003-06-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1621620A3 (fr) * 1999-09-01 2006-05-10 Genetech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP2290081A3 (fr) * 1999-12-23 2012-08-01 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
MXPA03003902A (es) 2000-11-03 2004-04-02 Univ California Polipeptidos de proquineticina, composiciones relacionadas y metodos.
CA2429179A1 (fr) 2000-11-14 2002-06-23 Bristol-Myers Squibb Company Polynucleotide codant pour une nouvelle serpine humaine (lsi-01) secretee a partir des cellules lymphoides
DE10106835A1 (de) * 2001-02-14 2002-09-05 Basf Lynx Bioscience Ag Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen
AU2002229091A1 (en) * 2001-06-20 2003-01-08 Genentech, Inc. Secreted polypeptide and their use in the treatment of bone disorders
WO2003088808A2 (fr) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
US7494804B2 (en) 2002-01-18 2009-02-24 Zymogenetics, Inc. Polynucleotide encoding cytokine receptor zcytor17 multimer
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
EP1513875A2 (fr) * 2002-05-10 2005-03-16 Serono Genetics Institute S.A. Polynucleotides et polypeptides krib et utilisations de ceux-ci dans le traitement de troubles metaboliques
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
US20060281146A1 (en) * 2002-09-11 2006-12-14 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2004031392A1 (fr) * 2002-10-02 2004-04-15 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Acides nucleiques et proteines homologues mipp1 impliques dans la regulation de l'homeostasie energetique
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP4912144B2 (ja) 2003-03-12 2012-04-11 ジェネンテック， インコーポレイテッド 造血促進のためのｂｖ８及び／又はｅｇ−ｖｅｇｆの使用
CA2527571A1 (fr) 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits et procedes d'identification, d'evaluation et de prevention, et therapie anticancereuse
SI1641822T1 (sl) 2003-07-08 2013-08-30 Genentech, Inc. IL-17 A/F heterologni polipeptidi in njihove terapevtske uporabe
WO2005056597A1 (fr) * 2003-12-09 2005-06-23 Riken Proteine receptrice du fc de l'immunoglobuline
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
KR101227817B1 (ko) * 2004-04-14 2013-01-29 제넨테크, 인크. 혈관 발달을 조절하기 위한 ｅｇｆｌ７ 길항제를 포함하는조성물 및 방법
JP2007536931A (ja) * 2004-05-12 2007-12-20 ジェネンテック・インコーポレーテッド 新規の遺伝子破壊、組成物およびそれらに関連する方法
DK1781682T3 (da) 2004-06-24 2013-06-03 Mayo Foundation B7-H5, et kostimulerende polypeptid
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
DE102004047968A1 (de) * 2004-10-01 2006-04-06 B.R.A.H.M.S Ag Bestimmung von Gastrokine 1 (GKN1) als Biomarker für Entzündungen und Infektionen
JP2008530132A (ja) 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
MX2007013609A (es) 2005-05-06 2008-01-24 Zymogenetics Inc Anticuerpos monoclonales de il-31 y meodos de uso.
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
JP2006333770A (ja) * 2005-06-01 2006-12-14 Japan Science & Technology Agency 血管炎（ａｎｇｉｉｔｉｓ）患者の血液細胞特異的遺伝子群
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
PL2500030T5 (pl) 2005-11-04 2019-02-28 Genentech, Inc. Zastosowanie inhibitorów drogi aktywacji dopełniacza w leczeniu chorób oczu
EP2594585A1 (fr) 2006-01-10 2013-05-22 Zymogenetics, Inc. Procédés de traitement de la douleur et l'inflammation dans des tissus neuronaux au moyen d'antagonistes IL-31
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
US8470979B2 (en) 2007-12-07 2013-06-25 Zymogenetics, Inc. Humanized antibody molecules specific for IL-31
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20110025649A (ko) 2008-05-05 2011-03-10 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
DK2280996T3 (en) 2008-05-06 2016-12-19 Genentech Inc Affinity matured CRIg VARIANTS
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
PE20160652A1 (es) 2009-05-05 2016-07-09 Novimmune Sa Anticuerpos que se unen a il-17f
PE20120902A1 (es) 2009-05-08 2012-08-08 Genentech Inc Anticuerpos anti-egfl7 humanizados
WO2011027132A1 (fr) * 2009-09-03 2011-03-10 Cancer Research Technology Limited Inhibiteurs de clec14a
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
PL3026064T3 (pl) 2011-05-13 2019-05-31 Ganymed Pharmaceuticals Gmbh Przeciwciała do leczenia nowotworu z ekspresją klaudyny 6
WO2012177595A1 (fr) * 2011-06-21 2012-12-27 Oncofactor Corporation Compositions et méthodes pour la thérapie et le diagnostic du cancer
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
BR112016025312A2 (pt) 2014-05-01 2017-10-17 Genentech Inc variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
EP3368090A1 (fr) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
EP3368074A2 (fr) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anticorps et conjugués anti-facteur d

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
EP0758390B1 (fr) * 1994-04-26 2007-02-28 The Children's Medical Center Corporation Angiostatine et procede d'utilisation de ladite substance pour inhiber l'angiogenese
WO2000053756A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
WO2002008284A2 (fr) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
JP2002532054A (ja) * 1997-08-29 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２９個のヒト分泌タンパク質
US5968744A (en) * 1997-10-14 1999-10-19 Incyte Pharmaceticals, Inc. Human cornichon molecule
JP2002511231A (ja) * 1997-12-30 2002-04-16 カイロン コーポレイション 骨髄分泌タンパク質およびポリヌクレオチド
EP1056847A2 (fr) * 1998-02-27 2000-12-06 Sagami Chemical Research Center Proteines humaines possedant des domaines transmembranaires et adn codant ces proteines
PT1490386E (pt) * 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
WO1999050405A1 (fr) * 1998-03-31 1999-10-07 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant
AU2399300A (en) * 1999-03-08 2000-09-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
HUP0201757A3 (en) * 1999-06-30 2010-01-28 Corixa Corp Compositoins and methods for the therapy and diagnosis of lung cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0200690A3 *

Also Published As

Publication number Publication date
WO2002000690A3 (fr) 2003-03-13
AU2001278852A1 (en) 2002-01-08
WO2002000690A2 (fr) 2002-01-03
CA2412211A1 (fr) 2002-01-03
JP2004506413A (ja) 2004-03-04

Similar Documents

Publication Publication Date Title
US7135334B2 (en) PRO20044 nucleic acids
AU771751B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
JP6033531B2 (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法
EP1309620A2 (fr) Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese
US7265210B2 (en) Anti-PRO9821 antibodies
US20040043927A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU3514400A (en) Compositions and methods for the treatment of immune related diseases
CA2373915A1 (fr) Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
US20030224984A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2042597B1 (fr) Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
AU2003259607B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
CA2648051A1 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
ZA200103707B (en) Promotion or inhibition of angiogenesis and cardio-vascularization.
JP2015037408A (ja) 血管形成に関連する障害を診断及び治療するための組成物と方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030102

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20050608

17Q First examination report despatched

Effective date: 20050608

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YE, WEILAN

Inventor name: WOOD, WILLIAM, I.

Inventor name: WILLIAMS, P., MICKEY

Inventor name: WATANABE, COLIN, K.

Inventor name: STEPHAN, JEAN-PHILIPPE, F.

Inventor name: PAONI, NICHOLAS, F.

Inventor name: PAN, JAMES

Inventor name: MARSTERS, SCOT, A.

Inventor name: HILLAN, KENNETH, J.

Inventor name: GURNEY, AUSTIN, L.

Inventor name: GODOWSKI, PAUL, J.

Inventor name: GODDARD, AUDREY

Inventor name: GERRITSEN, MARY, E.

Inventor name: GERBER, HANSPETER

Inventor name: FERRARA, NAPOLEONE

Inventor name: BAKER, KEVIN, P.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100327